JPH0221548B2 - - Google Patents
Info
- Publication number
- JPH0221548B2 JPH0221548B2 JP56177847A JP17784781A JPH0221548B2 JP H0221548 B2 JPH0221548 B2 JP H0221548B2 JP 56177847 A JP56177847 A JP 56177847A JP 17784781 A JP17784781 A JP 17784781A JP H0221548 B2 JPH0221548 B2 JP H0221548B2
- Authority
- JP
- Japan
- Prior art keywords
- protein
- fragment
- specific
- assayed
- interest
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 141
- 108090000623 proteins and genes Proteins 0.000 claims description 141
- 239000012634 fragment Substances 0.000 claims description 115
- 238000000034 method Methods 0.000 claims description 72
- 238000003556 assay Methods 0.000 claims description 56
- 230000029087 digestion Effects 0.000 claims description 35
- 229940111202 pepsin Drugs 0.000 claims description 31
- 102000057297 Pepsin A Human genes 0.000 claims description 30
- 108090000284 Pepsin A Proteins 0.000 claims description 30
- 239000002245 particle Substances 0.000 claims description 25
- 210000002966 serum Anatomy 0.000 claims description 24
- 102000004190 Enzymes Human genes 0.000 claims description 21
- 108090000790 Enzymes Proteins 0.000 claims description 21
- 229940088598 enzyme Drugs 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- 239000004365 Protease Substances 0.000 claims description 10
- 230000002776 aggregation Effects 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 230000006862 enzymatic digestion Effects 0.000 claims description 10
- 238000004220 aggregation Methods 0.000 claims description 9
- 239000013566 allergen Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 230000004520 agglutination Effects 0.000 claims description 7
- 238000003018 immunoassay Methods 0.000 claims description 7
- 239000013060 biological fluid Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 229940124568 digestive agent Drugs 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 230000013777 protein digestion Effects 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 3
- 239000000376 reactant Substances 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 108090000526 Papain Proteins 0.000 claims description 2
- 102000004142 Trypsin Human genes 0.000 claims description 2
- 108090000631 Trypsin Proteins 0.000 claims description 2
- 229940055729 papain Drugs 0.000 claims description 2
- 235000019834 papain Nutrition 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 239000012588 trypsin Substances 0.000 claims description 2
- 239000012491 analyte Substances 0.000 claims 1
- 229960001322 trypsin Drugs 0.000 claims 1
- 239000004816 latex Substances 0.000 description 29
- 229920000126 latex Polymers 0.000 description 29
- 230000000890 antigenic effect Effects 0.000 description 28
- 102000036639 antigens Human genes 0.000 description 24
- 108091007433 antigens Proteins 0.000 description 24
- 239000000427 antigen Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- 102000011923 Thyrotropin Human genes 0.000 description 12
- 108010061174 Thyrotropin Proteins 0.000 description 12
- 230000002452 interceptive effect Effects 0.000 description 12
- 102000035195 Peptidases Human genes 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 108010017384 Blood Proteins Proteins 0.000 description 7
- 102000004506 Blood Proteins Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108010000521 Human Growth Hormone Proteins 0.000 description 3
- 102000002265 Human Growth Hormone Human genes 0.000 description 3
- 239000000854 Human Growth Hormone Substances 0.000 description 3
- 102000004576 Placental Lactogen Human genes 0.000 description 3
- 108010003044 Placental Lactogen Proteins 0.000 description 3
- 239000000381 Placental Lactogen Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 208000030961 allergic reaction Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 230000004850 proteinâprotein interaction Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 108010015046 cell aggregation factors Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 235000004355 Artemisia lactiflora Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001149956 Cladosporium herbarum Species 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 240000004585 Dactylis glomerata Species 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000891982 Homo sapiens Alpha-crystallin B chain Proteins 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000746983 Phleum pratense Species 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex⢠Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000004182 chemical digestion Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000045069 human CRYAB Human genes 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/825—Pretreatment for removal of interfering factors from sample
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æ¬çºæã¯ã¿ã³ãã¯è³ªã®å
ç«åŠçæ€å®æ³ã«é¢ã
ãã
ãã
è¡æž
ããã³ãã®ä»ã®çç©åŠçæµäœã«ãããç¹å®
ã®ã¿ã³ãã¯è³ªã®å ç«åŠçæ€å®æ³ã«ãããŠã¯ãæµäœ
äžã«ååšããä»ã®ç©è³ªã«ãããæ€å®ã«å¹²æžãèµ·ã
ãã®ãéåžžã§ãããäŸãã°ãããã®è¡æž äžã®å å
æ§ã®è£äœå åïŒcomplement factorïŒããã³ãªãŠ
ããå åã¯æ€å®ã«äœ¿çšããæäœãšåå¿ããŠå¹²æžã
èµ·ããåŸåããããæŽã«ãè¡æž äžã«ååšããä»ã®
ã¿ã³ãã¯è³ªã¯éç¹ç°çãªã¿ã³ãã¯è³ªâã¿ã³ãã¯è³ª
çžäºäœçšã«ãã€ãŠå¹²æžãèµ·ããåŸåãããããã
ããå¹²æžãæé€ããããã®ææ¡ã¯çš®çš®è¡ãããŠã
ããäŸãã°è£äœå åãŸãã¯ãªãŠããå åã«ããå¹²
æžã¯ãæ€å®ã«ãããŠæäœå šäœã䜿ã代ãã«æäœã®
ïŒabâ²ïŒ2ãã©ã°ã¡ã³ãã䜿ãããšã«ãã€ãŠé¿ãã
ããšãã§ãããïŒabâ²ïŒ2ãã©ã°ã¡ã³ãã¯æ€å®äžã§
ã¿ã³ãã¯è³ªã«å¯Ÿãå ç«ç¹ç°æ§ããã€ãè£äœå åã
ãã³ãªãŠããå åãšã¯åå¿ããªãããã®æè¡ã¯ã
ã¯ãã³ã³ã»ã€ã³ã¹ãã«ã¡ã³ã瀟ã®åºé¡ã«ä¿ãè±åœ
ç¹èš±ç¬¬2013688å·æ现æžã«èšèŒãããã®ã§è©³çŽ°ã«
ã€ããŠã¯åèšæ现æžãåç §ãããããéç¹ç°çãª
ã¿ã³ãã¯è³ªâã¿ã³ãã¯è³ªçžäºäœçšã®å¹æã¯ã±ã€ãª
ãããŒãå€ïŒchaotropic agentïŒã®äœ¿çšã«ãã€ãŠ
å®è³ªçã«è»œæžããããšãã§ããããã®ç¹ã«ã€ããŠ
ã¯ãã¯ãã³ã³ã»ã€ã³ã¹ãã«ã¡ã³ã瀟ã®åºé¡ã«ä¿ã
欧å·ç¹èš±ç¬¬0038181å·æ现æžã«èšèŒãããŠããã®
ã§è©³çŽ°ã¯åèšæ现æžãåç §ããããã
ã®ã¿ã³ãã¯è³ªã®å ç«åŠçæ€å®æ³ã«ãããŠã¯ãæµäœ
äžã«ååšããä»ã®ç©è³ªã«ãããæ€å®ã«å¹²æžãèµ·ã
ãã®ãéåžžã§ãããäŸãã°ãããã®è¡æž äžã®å å
æ§ã®è£äœå åïŒcomplement factorïŒããã³ãªãŠ
ããå åã¯æ€å®ã«äœ¿çšããæäœãšåå¿ããŠå¹²æžã
èµ·ããåŸåããããæŽã«ãè¡æž äžã«ååšããä»ã®
ã¿ã³ãã¯è³ªã¯éç¹ç°çãªã¿ã³ãã¯è³ªâã¿ã³ãã¯è³ª
çžäºäœçšã«ãã€ãŠå¹²æžãèµ·ããåŸåãããããã
ããå¹²æžãæé€ããããã®ææ¡ã¯çš®çš®è¡ãããŠã
ããäŸãã°è£äœå åãŸãã¯ãªãŠããå åã«ããå¹²
æžã¯ãæ€å®ã«ãããŠæäœå šäœã䜿ã代ãã«æäœã®
ïŒabâ²ïŒ2ãã©ã°ã¡ã³ãã䜿ãããšã«ãã€ãŠé¿ãã
ããšãã§ãããïŒabâ²ïŒ2ãã©ã°ã¡ã³ãã¯æ€å®äžã§
ã¿ã³ãã¯è³ªã«å¯Ÿãå ç«ç¹ç°æ§ããã€ãè£äœå åã
ãã³ãªãŠããå åãšã¯åå¿ããªãããã®æè¡ã¯ã
ã¯ãã³ã³ã»ã€ã³ã¹ãã«ã¡ã³ã瀟ã®åºé¡ã«ä¿ãè±åœ
ç¹èš±ç¬¬2013688å·æ现æžã«èšèŒãããã®ã§è©³çŽ°ã«
ã€ããŠã¯åèšæ现æžãåç §ãããããéç¹ç°çãª
ã¿ã³ãã¯è³ªâã¿ã³ãã¯è³ªçžäºäœçšã®å¹æã¯ã±ã€ãª
ãããŒãå€ïŒchaotropic agentïŒã®äœ¿çšã«ãã€ãŠ
å®è³ªçã«è»œæžããããšãã§ããããã®ç¹ã«ã€ããŠ
ã¯ãã¯ãã³ã³ã»ã€ã³ã¹ãã«ã¡ã³ã瀟ã®åºé¡ã«ä¿ã
欧å·ç¹èš±ç¬¬0038181å·æ现æžã«èšèŒãããŠããã®
ã§è©³çŽ°ã¯åèšæ现æžãåç §ããããã
è¡æž
ã¿ã³ãã¯è³ªã«ããå¹²æžã¯éã¿ã³ãã¯è³ªæå
ïŒãã®èªã¯ãããã³ãå«ãïŒã®å ç«åŠçæ€å®ã«ã
ããŠãåé¡ãšãªããäŸãã°ãè¡æž ã¿ã³ãã¯è³ªã¯æ€
å®åå¿ã«ãããŠå¹²æžãèµ·ããå¯èœæ§ãããã ãã§
ãªããæ€å®äžã®æåãè¡æž ã¿ã³ãã¯è³ªãšçµåããŠ
ããŸãã®ã§ãæ€å®ãå¯èœã«ããããã«ã¯æåããŸ
ãè¡æž ã¿ã³ãã¯è³ªããéé¢ãããå¿ èŠããããã
ãããªãããã®çš®ã®å¹²æžã¯é µçŽ äŸãã°ããã·ã³ã
䜿çšããŠè¡æž ã¿ã³ãã¯è³ªãæåã«æ¶åããŠããŸã
ããšã«ãã€ãŠé¿ããããšãã§ããïŒéã¿ã³ãã¯è³ª
æåã¯åœ±é¿ãåããªãïŒããã®é µçŽ ã¯æ€å®ã®åã«
äžæŽ»æ§åãŸãã¯å解ããŠããŸãããã®æäœæé ã¯
äŸãã°J.Clin.Endocrinol.Metab.42ã189ïŒ1976ïŒ
ã«èšèŒãããŠãããããã«ã¯è¡æž äžã®éãããã
ãªã¬ã³ãã®æ€å®ã«ãã®æè¡ãåºãå¿çšã§ããããš
ã瀺åãããŠããïŒããããªãããããããªã¬ã³
ãã¯é µçŽ ã«ãã€ãŠå解ãããã®ã§ããã«å«ãŸããª
ãããšã¯èšããŸã§ããªãïŒã
ïŒãã®èªã¯ãããã³ãå«ãïŒã®å ç«åŠçæ€å®ã«ã
ããŠãåé¡ãšãªããäŸãã°ãè¡æž ã¿ã³ãã¯è³ªã¯æ€
å®åå¿ã«ãããŠå¹²æžãèµ·ããå¯èœæ§ãããã ãã§
ãªããæ€å®äžã®æåãè¡æž ã¿ã³ãã¯è³ªãšçµåããŠ
ããŸãã®ã§ãæ€å®ãå¯èœã«ããããã«ã¯æåããŸ
ãè¡æž ã¿ã³ãã¯è³ªããéé¢ãããå¿ èŠããããã
ãããªãããã®çš®ã®å¹²æžã¯é µçŽ äŸãã°ããã·ã³ã
䜿çšããŠè¡æž ã¿ã³ãã¯è³ªãæåã«æ¶åããŠããŸã
ããšã«ãã€ãŠé¿ããããšãã§ããïŒéã¿ã³ãã¯è³ª
æåã¯åœ±é¿ãåããªãïŒããã®é µçŽ ã¯æ€å®ã®åã«
äžæŽ»æ§åãŸãã¯å解ããŠããŸãããã®æäœæé ã¯
äŸãã°J.Clin.Endocrinol.Metab.42ã189ïŒ1976ïŒ
ã«èšèŒãããŠãããããã«ã¯è¡æž äžã®éãããã
ãªã¬ã³ãã®æ€å®ã«ãã®æè¡ãåºãå¿çšã§ããããš
ã瀺åãããŠããïŒããããªãããããããªã¬ã³
ãã¯é µçŽ ã«ãã€ãŠå解ãããã®ã§ããã«å«ãŸããª
ãããšã¯èšããŸã§ããªãïŒã
ã¿ã³ãã¯è³ªã®é
µçŽ çæ¶åã¯ãã¡ããåšç¥ã®ããš
ã§ãããåèšæ¶åã«ããã¿ã³ãã¯è³ªååã¯äžå±€å°
ãããã©ã°ã¡ã³ãã«å解ããããããã¯äŸãã°ã¿
ã³ãã¯è³ªã®ã¢ããé žé åã決å®ããéã«äœ¿ãæè¡
ã§ããããã®åæã®æ©æ§ããã³åŸã€ãŠãã©ã°ã¡ã³
ãã®æ£ç¢ºãªæ§é ã¯äœ¿çšããé µçŽ ããã³æ¶åæ¡ä»¶
ïŒäŸãã°æéã枩床ããã³PHïŒã«ãã€ãŠå€åããã
çç©åŠçã«æŽ»æ§ãªã¿ã³ãã¯è³ªã®é µçŽ çæ¶åã«ãã€
ãŠçç©åŠçãŸãã¯å ç«åŠçãªæŽ»æ§ãããçšåºŠä¿æ
ãããã©ã°ã¡ã³ãã圢æã§ããããšããè¥å¹²ã®äº
äŸã«ã€ããŠå ±åãããŠãããäŸãã°ïŒªâïŒ
BluardâDeconinkçBiochem J.171ïŒ1978ïŒ321
ã327ïŒU.J.LeuvisçãGrowth Hormone and
Related PeptidesãExcerpta MedicaïŒã¢ã ã¹ã
ã«ãã ïŒ1976ã第64é ïŒU.J.LeuvisçBiochem.
Biophys.Res.Commun.67ã617ïŒ1975ïŒãããããª
ãããé µçŽ çæ¶åãéã¿ã³ãã¯è³ªæåã®æ€å®ã«ã
ããè¡æž ã¿ã³ãã¯è³ªã®å解çšãšããŠææ¡ãããŠã
ãéãã«ãããŠã¯ããã®æ¶åã¯ã¿ã³ãã¯è³ªå¹²æžã®
å®å šãªæé€ã®ããã«å®æœãããã®ãããªãã¡éã¿
ã³ãã¯è³ªæåã®æ€å®ã«ãããŠè¡æž ã¿ã³ãã¯è³ªãå¹²
æžãèµ·ãããªãããã«ãããã¿ã³ãã¯è³ªãå解ã
ãŠããŸãããã«å®æœãããã®ã§ãããªãã
ã§ãããåèšæ¶åã«ããã¿ã³ãã¯è³ªååã¯äžå±€å°
ãããã©ã°ã¡ã³ãã«å解ããããããã¯äŸãã°ã¿
ã³ãã¯è³ªã®ã¢ããé žé åã決å®ããéã«äœ¿ãæè¡
ã§ããããã®åæã®æ©æ§ããã³åŸã€ãŠãã©ã°ã¡ã³
ãã®æ£ç¢ºãªæ§é ã¯äœ¿çšããé µçŽ ããã³æ¶åæ¡ä»¶
ïŒäŸãã°æéã枩床ããã³PHïŒã«ãã€ãŠå€åããã
çç©åŠçã«æŽ»æ§ãªã¿ã³ãã¯è³ªã®é µçŽ çæ¶åã«ãã€
ãŠçç©åŠçãŸãã¯å ç«åŠçãªæŽ»æ§ãããçšåºŠä¿æ
ãããã©ã°ã¡ã³ãã圢æã§ããããšããè¥å¹²ã®äº
äŸã«ã€ããŠå ±åãããŠãããäŸãã°ïŒªâïŒ
BluardâDeconinkçBiochem J.171ïŒ1978ïŒ321
ã327ïŒU.J.LeuvisçãGrowth Hormone and
Related PeptidesãExcerpta MedicaïŒã¢ã ã¹ã
ã«ãã ïŒ1976ã第64é ïŒU.J.LeuvisçBiochem.
Biophys.Res.Commun.67ã617ïŒ1975ïŒãããããª
ãããé µçŽ çæ¶åãéã¿ã³ãã¯è³ªæåã®æ€å®ã«ã
ããè¡æž ã¿ã³ãã¯è³ªã®å解çšãšããŠææ¡ãããŠã
ãéãã«ãããŠã¯ããã®æ¶åã¯ã¿ã³ãã¯è³ªå¹²æžã®
å®å šãªæé€ã®ããã«å®æœãããã®ãããªãã¡éã¿
ã³ãã¯è³ªæåã®æ€å®ã«ãããŠè¡æž ã¿ã³ãã¯è³ªãå¹²
æžãèµ·ãããªãããã«ãããã¿ã³ãã¯è³ªãå解ã
ãŠããŸãããã«å®æœãããã®ã§ãããªãã
æ¬çºæè
ã¯éã¿ã³ãã¯è³ªæåã®å
ç«åŠçæ€å®ã«
ãããå¹²æžã¿ã³ãã¯è³ªã®é µçŽ çæ¶åã«ãã€ãŠåŸã
ããå©ç¹ããã¿ã³ãã¯è³ªæåã®å ç«åŠçæ€å®ã«ã
ããŠããä»ã®å©ç¹ãšãšãã«åŸãããããšãèŠãåº
ãããããªãã¡ãæ¬çºæè ã¯é©ãã¹ãããšã«ãïŒ
皮以äžã®ã¿ã³ãã¯è³ªãå«ã¿ããã®ãã¡ã®ïŒçš®ã ã
ãæ€å®å¯Ÿè±¡ã¿ã³ãã¯è³ªã§ãããã®ãå«ã液äœã«ã¿
ã³ãã¯è³ªæ¶åãé©çšãããã®åŸã§å¯Ÿè±¡ã¿ã³ãã¯è³ª
ãä»ã®ã¿ã³ãã¯è³ªããã®å¹²æžãªãã«æ€å®ã§ããã
ãšãèŠãåºããã
ãããå¹²æžã¿ã³ãã¯è³ªã®é µçŽ çæ¶åã«ãã€ãŠåŸã
ããå©ç¹ããã¿ã³ãã¯è³ªæåã®å ç«åŠçæ€å®ã«ã
ããŠããä»ã®å©ç¹ãšãšãã«åŸãããããšãèŠãåº
ãããããªãã¡ãæ¬çºæè ã¯é©ãã¹ãããšã«ãïŒ
皮以äžã®ã¿ã³ãã¯è³ªãå«ã¿ããã®ãã¡ã®ïŒçš®ã ã
ãæ€å®å¯Ÿè±¡ã¿ã³ãã¯è³ªã§ãããã®ãå«ã液äœã«ã¿
ã³ãã¯è³ªæ¶åãé©çšãããã®åŸã§å¯Ÿè±¡ã¿ã³ãã¯è³ª
ãä»ã®ã¿ã³ãã¯è³ªããã®å¹²æžãªãã«æ€å®ã§ããã
ãšãèŠãåºããã
æ¬çºæã®äžã€ã®ç®çã¯ãæ€å®å¯Ÿè±¡ã®ã¿ã³ãã¯è³ª
ããã³ãã®ä»ã®ïŒçš®ãŸãã¯ãã以äžã®æ€å®å¯Ÿè±¡å€
ã®ã¿ã³ãã¯è³ªãå«ã液äœè©Šæãšã¿ã³ãã¯è³ªæ¶åå€
ãšãæ··åããŠãåèšã®å¯Ÿè±¡ã¿ã³ãã¯è³ªããåŸãã
ãæ··åç©äžã§åèšã®å¯Ÿè±¡ã¿ã³ãã¯è³ªã«é¢ããŠã ã
ç¹å®æ§ã®æåæ§æ±ºå®å åãåèšæ··åç©äžã«æäŸã
ãæ¡ä»¶äžã§ã¿ã³ãã¯è³ªæ¶åãè¡ãããšã«ãã€ãŠå
èšã®å¯Ÿè±¡å€ã¿ã³ãã¯è³ªã«ãå¹²æžã軜æžãªããæé€
ãããããŠåèšã®æåæ§æ±ºå®å åãæ€å®ãããã
ãŠãã®çµæãã液äœè©Šæäžã«ååšããåèšã®å¯Ÿè±¡
ã¿ã³ãã¯è³ªã®éã決å®ããããšããæãã察象å€
ã¿ã³ãã¯è³ªïŒçš®ãŸãã¯ãã以äžãå«ã液äœè©Šæäž
ã®å¯Ÿè±¡ã¿ã³ãã¯è³ªã®å ç«åŠçæ€å®æ³ãæäŸããã
ãšã«ããã
ããã³ãã®ä»ã®ïŒçš®ãŸãã¯ãã以äžã®æ€å®å¯Ÿè±¡å€
ã®ã¿ã³ãã¯è³ªãå«ã液äœè©Šæãšã¿ã³ãã¯è³ªæ¶åå€
ãšãæ··åããŠãåèšã®å¯Ÿè±¡ã¿ã³ãã¯è³ªããåŸãã
ãæ··åç©äžã§åèšã®å¯Ÿè±¡ã¿ã³ãã¯è³ªã«é¢ããŠã ã
ç¹å®æ§ã®æåæ§æ±ºå®å åãåèšæ··åç©äžã«æäŸã
ãæ¡ä»¶äžã§ã¿ã³ãã¯è³ªæ¶åãè¡ãããšã«ãã€ãŠå
èšã®å¯Ÿè±¡å€ã¿ã³ãã¯è³ªã«ãå¹²æžã軜æžãªããæé€
ãããããŠåèšã®æåæ§æ±ºå®å åãæ€å®ãããã
ãŠãã®çµæãã液äœè©Šæäžã«ååšããåèšã®å¯Ÿè±¡
ã¿ã³ãã¯è³ªã®éã決å®ããããšããæãã察象å€
ã¿ã³ãã¯è³ªïŒçš®ãŸãã¯ãã以äžãå«ã液äœè©Šæäž
ã®å¯Ÿè±¡ã¿ã³ãã¯è³ªã®å ç«åŠçæ€å®æ³ãæäŸããã
ãšã«ããã
æ¬çºæã®æ¹æ³ã«ãããŠã¯ããããŠãã¯çç©ç±æ¥
ã§ãã液äœè©ŠæãäŸãã°è¡æž ãšãã¿ã³ãã¯è³ªæ¶å
ãèµ·ããè©Šè¬ãšãåå¿ãããããã®è©Šè¬ãšããŠå
åŠç©è³ªäŸãã°èåã·ã¢ã³ããžã¡ãã«ã¹ã«ããã·
ãïŒèåæ°ŽçŽ é žããžããªãã¬ã€ããŒã«ãŸãã¯åæ§
ãªä»ã®å ¬ç¥ã®è©Šè¬ã䜿ããããé µçŽ ã䜿ãã®ã奜
ãŸããã奜ãŸãããããã¢ãŒãŒã¯ããã·ã³ã§ãã
ããä»ã®ãããã¢ãŒãŒäŸãã°ããã€ã³ããã³ããª
ãã·ã³ã䜿ãããç°ãªãçš®é¡ã®é µçŽ ã¯ç°ãªãæ§
åãããªãã¡ãããªããããéã®äžã®ç°ãªãç¹ã§
ç°ãªãé床ã§ã¿ã³ãã¯è³ªãå解ãããããããã
ãã®æ€å®ã«ãããŠæé©ã®é µçŽ ããã³æ¡ä»¶ïŒäŸãã°
PHãæéãã€ãªã³åŒ·åºŠã枩床ãïŒã決ããããã®
äºåçãªè©Šéšãè¡ãªãã®ãæãŸããã以äžãæ¬æ
现æžã§ã¯äž»ã«é µçŽ çæ¶åã«ã€ããŠèšèŒããããå
åŠçæ¶åã䜿ãããã®ã§ããïŒé µçŽ ã«ããæ¶åã
ã奜ãŸããªããïŒã
ã§ãã液äœè©ŠæãäŸãã°è¡æž ãšãã¿ã³ãã¯è³ªæ¶å
ãèµ·ããè©Šè¬ãšãåå¿ãããããã®è©Šè¬ãšããŠå
åŠç©è³ªäŸãã°èåã·ã¢ã³ããžã¡ãã«ã¹ã«ããã·
ãïŒèåæ°ŽçŽ é žããžããªãã¬ã€ããŒã«ãŸãã¯åæ§
ãªä»ã®å ¬ç¥ã®è©Šè¬ã䜿ããããé µçŽ ã䜿ãã®ã奜
ãŸããã奜ãŸãããããã¢ãŒãŒã¯ããã·ã³ã§ãã
ããä»ã®ãããã¢ãŒãŒäŸãã°ããã€ã³ããã³ããª
ãã·ã³ã䜿ãããç°ãªãçš®é¡ã®é µçŽ ã¯ç°ãªãæ§
åãããªãã¡ãããªããããéã®äžã®ç°ãªãç¹ã§
ç°ãªãé床ã§ã¿ã³ãã¯è³ªãå解ãããããããã
ãã®æ€å®ã«ãããŠæé©ã®é µçŽ ããã³æ¡ä»¶ïŒäŸãã°
PHãæéãã€ãªã³åŒ·åºŠã枩床ãïŒã決ããããã®
äºåçãªè©Šéšãè¡ãªãã®ãæãŸããã以äžãæ¬æ
现æžã§ã¯äž»ã«é µçŽ çæ¶åã«ã€ããŠèšèŒããããå
åŠçæ¶åã䜿ãããã®ã§ããïŒé µçŽ ã«ããæ¶åã
ã奜ãŸããªããïŒã
æ€å®å¯Ÿè±¡ã®ã¿ã³ãã¯è³ªããã³ãã®ä»ã®ïŒçš®ãŸã
ã¯ãã以äžã®ã¿ã³ãã¯è³ªïŒä»¥äžããå¹²æžã¿ã³ãã¯
質ããšåŒã¶ïŒãå«ãã被æ€å®æ¶²äœããããã¢ãŒãŒ
äŸãã°ããã·ã³ãšæ··åãããè¡æž ã®å Žåããå¹²æž
ã¿ã³ãã¯è³ªãã¯äŸãã°è£äœå åããªããŠã å å
ïŒIgMããã³IgMïŒãã¢ã«ããã³ããã¬âã¢ã«ã¢ã
ãã³ããã³çš®é¡ã®æäœã§ãããæ¶åã®åŸã®æ€å®äž
ã«ãå¹²æžã¿ã³ãã¯è³ªããå°ãªããšãå¹²æžãèµ·ãã
ãªãçšåºŠã«ãŸã§ãå¹²æžã¿ã³ãã¯è³ªããå解ããã
ãã«é µçŽ çæ¶åãè¡ãªããäžè¬çã«ã¯ïŒåã®ãå¹²
æžã¿ã³ãã¯è³ªãã¯ïŒåãŸãã¯ãã以äžã®ãã©ã°ã¡
ã³ãã«å解ããã察象ã¿ã³ãã¯è³ªãé µçŽ ã«ãã€ãŠ
ãã©ã°ã¡ã³ãã«å解ããããããŸãã¯å Žåã«ãã€
ãŠã¯é µçŽ ã«ããå®è³ªçãªåœ±é¿ã¯åããªããæ¬çºæ
ã®ç®çã®ããã«ã¯ãæ€å®å¯Ÿè±¡ã¿ã³ãã¯è³ªããã©ã°
ã¡ã³ãã«å解ãããåŠãã¯ååãšããŠåé¡ã§ãª
ããæãéèŠãªç¹ã¯ããå¹²æžã¿ã³ãã¯è³ªããæ€å®
äžã«å¹²æžãèµ·ãããªããªãããã«æ¶²äœè©Šæãæ¶å
ã«ãã€ãŠå€æ§ãããããšã§ãããæ¶å段éã§ãå¹²
æžã¿ã³ãã¯è³ªãããã©ã°ã¡ã³ãã«å解ããã®ãæ®
éã§ããããããæ¬çºæã«ããã°å¹²æžã¿ã³ãã¯è³ª
ãæ¶åã«ãã圱é¿ãå®è³ªçã«åããã«å¯Ÿè±¡ã¿ã³ã
ã¯è³ªããã©ã°ã¡ã³ãã«å解ã§ããããå¹²æžã¿ã³ã
ã¯è³ªãã«ããå¹²æžãåããã«ãã©ã°ã¡ã³ãã«ãªã€
ãã¿ã³ãã¯è³ªãã²ãã€ã¥ãæ€å®ããã
ã¯ãã以äžã®ã¿ã³ãã¯è³ªïŒä»¥äžããå¹²æžã¿ã³ãã¯
質ããšåŒã¶ïŒãå«ãã被æ€å®æ¶²äœããããã¢ãŒãŒ
äŸãã°ããã·ã³ãšæ··åãããè¡æž ã®å Žåããå¹²æž
ã¿ã³ãã¯è³ªãã¯äŸãã°è£äœå åããªããŠã å å
ïŒIgMããã³IgMïŒãã¢ã«ããã³ããã¬âã¢ã«ã¢ã
ãã³ããã³çš®é¡ã®æäœã§ãããæ¶åã®åŸã®æ€å®äž
ã«ãå¹²æžã¿ã³ãã¯è³ªããå°ãªããšãå¹²æžãèµ·ãã
ãªãçšåºŠã«ãŸã§ãå¹²æžã¿ã³ãã¯è³ªããå解ããã
ãã«é µçŽ çæ¶åãè¡ãªããäžè¬çã«ã¯ïŒåã®ãå¹²
æžã¿ã³ãã¯è³ªãã¯ïŒåãŸãã¯ãã以äžã®ãã©ã°ã¡
ã³ãã«å解ããã察象ã¿ã³ãã¯è³ªãé µçŽ ã«ãã€ãŠ
ãã©ã°ã¡ã³ãã«å解ããããããŸãã¯å Žåã«ãã€
ãŠã¯é µçŽ ã«ããå®è³ªçãªåœ±é¿ã¯åããªããæ¬çºæ
ã®ç®çã®ããã«ã¯ãæ€å®å¯Ÿè±¡ã¿ã³ãã¯è³ªããã©ã°
ã¡ã³ãã«å解ãããåŠãã¯ååãšããŠåé¡ã§ãª
ããæãéèŠãªç¹ã¯ããå¹²æžã¿ã³ãã¯è³ªããæ€å®
äžã«å¹²æžãèµ·ãããªããªãããã«æ¶²äœè©Šæãæ¶å
ã«ãã€ãŠå€æ§ãããããšã§ãããæ¶å段éã§ãå¹²
æžã¿ã³ãã¯è³ªãããã©ã°ã¡ã³ãã«å解ããã®ãæ®
éã§ããããããæ¬çºæã«ããã°å¹²æžã¿ã³ãã¯è³ª
ãæ¶åã«ãã圱é¿ãå®è³ªçã«åããã«å¯Ÿè±¡ã¿ã³ã
ã¯è³ªããã©ã°ã¡ã³ãã«å解ã§ããããå¹²æžã¿ã³ã
ã¯è³ªãã«ããå¹²æžãåããã«ãã©ã°ã¡ã³ãã«ãªã€
ãã¿ã³ãã¯è³ªãã²ãã€ã¥ãæ€å®ããã
察象ã¿ã³ãã¯è³ªããä»ã®å¯Ÿè±¡å€ã¿ã³ãã¯è³ªã«ã
ãå¹²æžãåããã«æ€å®ã§ãããªãã°ãæ¶åã®æ£ç¢º
ãªæ©æ§ã¯é倧ãªäºã§ã¯ãªããæãäžè¬çããã€å¥œ
ãŸããã¯ã察象å€ã¿ã³ãã¯è³ªãæ¶å段éã§å解ã
ãã察象ã¿ã³ãã¯è³ªãïŒå¿ ããããã¹ãŠã§ã¯ãªã
ãïŒäžè¬çã«ã¯ãã©ã°ã¡ã³ãã«å解ããããã®æ©
æ§ã¯ãåœç¶ã®ããšãªãããã¿ã³ãã¯è³ªã®æ§è³ªãé µ
çŽ ã®æ§è³ªãããã«æ¶åãè¡ãªãããæ¡ä»¶ã«ãã€ãŠ
å€ããã
ãå¹²æžãåããã«æ€å®ã§ãããªãã°ãæ¶åã®æ£ç¢º
ãªæ©æ§ã¯é倧ãªäºã§ã¯ãªããæãäžè¬çããã€å¥œ
ãŸããã¯ã察象å€ã¿ã³ãã¯è³ªãæ¶å段éã§å解ã
ãã察象ã¿ã³ãã¯è³ªãïŒå¿ ããããã¹ãŠã§ã¯ãªã
ãïŒäžè¬çã«ã¯ãã©ã°ã¡ã³ãã«å解ããããã®æ©
æ§ã¯ãåœç¶ã®ããšãªãããã¿ã³ãã¯è³ªã®æ§è³ªãé µ
çŽ ã®æ§è³ªãããã«æ¶åãè¡ãªãããæ¡ä»¶ã«ãã€ãŠ
å€ããã
æ¶åã®çµæããå¹²æžã¿ã³ãã¯è³ªãããã©ã°ã¡ã³
ãã«å解ãã察象ã¿ã³ãã¯è³ªãå®è³ªçãªåœ±é¿ãå
ããªãå Žåã察象ã¿ã³ãã¯è³ªå šäœãæåæ§æ±ºå®å
åãšããŠäœ¿ã€ãŠæ€å®ã§ãããæ¬çºæã®æ¹æ³ã§æ€å®
ã§ããã¿ã³ãã¯è³ªã®ïŒã€ã¯ãããè¡æž äžã®ç²ç¶è º
åºæ¿ãã«ã¢ã³ïŒTSHïŒã§ãããããã·ã³ã䜿ã€
ãŠé µçŽ çæ¶åãè¡ãªããšTSHã¯ã»ãšãã©åœ±é¿ã
åãããæ¶åã®åŸã§å šTSHã«å¯Ÿããæ€å®ããã
ããšãã§ããããããè¡æž äžã®å¹²æžã¿ã³ãã¯è³ªã¯
ãã©ã°ã¡ã³ãã«å解ãããããã®ãã©ã°ã¡ã³ãã¯
æ€å®ã«ãããŠå¹²æžãèµ·ãããªãã
ãã«å解ãã察象ã¿ã³ãã¯è³ªãå®è³ªçãªåœ±é¿ãå
ããªãå Žåã察象ã¿ã³ãã¯è³ªå šäœãæåæ§æ±ºå®å
åãšããŠäœ¿ã€ãŠæ€å®ã§ãããæ¬çºæã®æ¹æ³ã§æ€å®
ã§ããã¿ã³ãã¯è³ªã®ïŒã€ã¯ãããè¡æž äžã®ç²ç¶è º
åºæ¿ãã«ã¢ã³ïŒTSHïŒã§ãããããã·ã³ã䜿ã€
ãŠé µçŽ çæ¶åãè¡ãªããšTSHã¯ã»ãšãã©åœ±é¿ã
åãããæ¶åã®åŸã§å šTSHã«å¯Ÿããæ€å®ããã
ããšãã§ããããããè¡æž äžã®å¹²æžã¿ã³ãã¯è³ªã¯
ãã©ã°ã¡ã³ãã«å解ãããããã®ãã©ã°ã¡ã³ãã¯
æ€å®ã«ãããŠå¹²æžãèµ·ãããªãã
æãå€ãã®å Žåãå¹²æžã¿ã³ãã¯è³ªã察象ã¿ã³ã
ã¯è³ªããšãã«æ¶åãããŠãã©ã°ã¡ã³ãã圢æã
ããæ¬çºæã®ç¹è²ãšãããšããã«ããã°ã察象ã¿
ã³ãã¯è³ªãããã®å¯Ÿè±¡ã¿ã³ãã¯è³ªã«é¢ããŠã ãã
ã®ã¿ã³ãã¯è³ªã®æåãšããŠã®ç¹åŸŽã瀺ããã©ã°ã¡
ã³ããæåç¹å®æ§ïŒdistinctiveïŒãã©ã°ã¡ã³ãã
æ··åç©äžã«åœ¢æãããããªæ¡ä»¶ã§æ¶åãè¡ãªãã
次ã«ãã®ãã©ã°ã¡ã³ããæ€å®ããã
ã¯è³ªããšãã«æ¶åãããŠãã©ã°ã¡ã³ãã圢æã
ããæ¬çºæã®ç¹è²ãšãããšããã«ããã°ã察象ã¿
ã³ãã¯è³ªãããã®å¯Ÿè±¡ã¿ã³ãã¯è³ªã«é¢ããŠã ãã
ã®ã¿ã³ãã¯è³ªã®æåãšããŠã®ç¹åŸŽã瀺ããã©ã°ã¡
ã³ããæåç¹å®æ§ïŒdistinctiveïŒãã©ã°ã¡ã³ãã
æ··åç©äžã«åœ¢æãããããªæ¡ä»¶ã§æ¶åãè¡ãªãã
次ã«ãã®ãã©ã°ã¡ã³ããæ€å®ããã
æåç¹å®æ§ãã©ã°ã¡ã³ããåå®ããããã«ã¯ã
æ€å®å¯Ÿè±¡ã¿ã³ãã¯è³ªè©Šæãé µçŽ çã«æ¶åããçæ
ããã¿ã³ãã¯è³ªãŸãã¯ããªãããããã¯ãããã°
ã©ãã€ãŒã«ãã€ãŠåé¢ããã次ã«äž»ãªçš®é¡ã®ãã©
ã°ã¡ã³ããããããæè¡æž ç£çåç©äŸãã°ãŠãµã®
ã«æ³šå°ãããéåžžããã®ãã¡ã®ïŒçš®ã®ãã©ã°ã¡ã³
ããé«ãçµåæ§ãŸãã¯å䟡ãæã€æè¡æž ãç£çã
ãããã®ãã©ã°ã¡ã³ããéžã¶ã¹ãæåæå®æ§ãã©
ã°ã¡ã³ãã§ãããããšã®ã¿ã³ãã¯è³ªå šååã®äžã§
ã¯ãã®ãã©ã°ã¡ã³ãã¯ååå éšã«é ãããŠããã
ãç«äœé害ã«ããäžæŽ»æ§ã§ããããšããããã®äž
掻æ§ã¯æå掻æ§ã瀺ããªãïŒãŸãã¯ååå šäœã®æ
å掻æ§ã«é¢äžããªãïŒããšããããšããããšã¯æ³š
ç®ã«å€ããããã®ããã«ããŠç£çããæåæ§ç¹å®
æ§ãã©ã°ã¡ã³ãã«å¯Ÿããæè¡æž ã¯ãæ¶åãããè¡
æž äžã®ãã©ã°ã¡ã³ãã®æ€å®ã«äœ¿ãã®ã奜ãŸããã
æ€å®å¯Ÿè±¡ã¿ã³ãã¯è³ªè©Šæãé µçŽ çã«æ¶åããçæ
ããã¿ã³ãã¯è³ªãŸãã¯ããªãããããã¯ãããã°
ã©ãã€ãŒã«ãã€ãŠåé¢ããã次ã«äž»ãªçš®é¡ã®ãã©
ã°ã¡ã³ããããããæè¡æž ç£çåç©äŸãã°ãŠãµã®
ã«æ³šå°ãããéåžžããã®ãã¡ã®ïŒçš®ã®ãã©ã°ã¡ã³
ããé«ãçµåæ§ãŸãã¯å䟡ãæã€æè¡æž ãç£çã
ãããã®ãã©ã°ã¡ã³ããéžã¶ã¹ãæåæå®æ§ãã©
ã°ã¡ã³ãã§ãããããšã®ã¿ã³ãã¯è³ªå šååã®äžã§
ã¯ãã®ãã©ã°ã¡ã³ãã¯ååå éšã«é ãããŠããã
ãç«äœé害ã«ããäžæŽ»æ§ã§ããããšããããã®äž
掻æ§ã¯æå掻æ§ã瀺ããªãïŒãŸãã¯ååå šäœã®æ
å掻æ§ã«é¢äžããªãïŒããšããããšããããšã¯æ³š
ç®ã«å€ããããã®ããã«ããŠç£çããæåæ§ç¹å®
æ§ãã©ã°ã¡ã³ãã«å¯Ÿããæè¡æž ã¯ãæ¶åãããè¡
æž äžã®ãã©ã°ã¡ã³ãã®æ€å®ã«äœ¿ãã®ã奜ãŸããã
æ¬çºæã®å¥œãŸããæ¹æ³ã®éèŠãªç¹åŸŽã¯ã察象ã¿
ã³ãã¯è³ªãšä»ã®ã¿ã³ãã¯è³ªãšã®æ··åç©ã«å¯ŸããŠã³
ã³ãããŒã«ãããæ¶åãè¡ãªãããšã«ããã皮皮
ã®ãã©ã°ã¡ã³ããåŸããã®ãã¡ã®å°ãªããšãïŒçš®
ã¯æ€å®ã®å¯Ÿè±¡ãšãªã€ãŠããç¹å®ã®ã¿ã³ãã¯è³ªã«å¯Ÿ
ããŠã®ã¿æåç¹å®æ§ã§ãããåŸã€ãŠãã®æ€å®ã«ã
ãããšã®è©Šæäžã®å¯Ÿè±¡ã¿ã³ãã¯è³ªã®ååšãšéãšã
瀺ãããã
ã³ãã¯è³ªãšä»ã®ã¿ã³ãã¯è³ªãšã®æ··åç©ã«å¯ŸããŠã³
ã³ãããŒã«ãããæ¶åãè¡ãªãããšã«ããã皮皮
ã®ãã©ã°ã¡ã³ããåŸããã®ãã¡ã®å°ãªããšãïŒçš®
ã¯æ€å®ã®å¯Ÿè±¡ãšãªã€ãŠããç¹å®ã®ã¿ã³ãã¯è³ªã«å¯Ÿ
ããŠã®ã¿æåç¹å®æ§ã§ãããåŸã€ãŠãã®æ€å®ã«ã
ãããšã®è©Šæäžã®å¯Ÿè±¡ã¿ã³ãã¯è³ªã®ååšãšéãšã
瀺ãããã
以äžã«è©³çŽ°ã«è¿°ã¹ãããã«æ¬çºæã¯å
ç«ã°ãã
ãªã³ïŒ¥ïŒIgEïŒã®æ€å®ã«ç¹ã«æçšã§ããããä»ã®
å ç«ã°ãããªã³ãä»ã®ã¿ã³ãã¯è³ªäŸãã°TSHïŒç²
ç¶è ºåºæ¿ãã«ã¢ã³ïŒãåµå·£åºæ¿ãã«ã¢ã³ïŒFSHïŒ
ããã³ããæé·ãã«ã¢ã³ïŒHGHïŒã«ã䜿ããã
ãããã®ã¿ã³ãã¯è³ªã¯ãã¹ãŠæ¯èŒç倧ããªååé
ïŒäŸãã°ååé50000以äžïŒãæã€æ¯èŒçå°ããªã¿
ã³ãã¯è³ªäŸãã°ã€ã³ã·ãŠãªã³ãã¢ã³ãžãªãã³ã·ã³
ããã³ã¯ãæ¬çºææ¹æ³ã«ããæ€å®ãããå°é£
ã§ãããããã¯ã液äœè©Šæã®æ¶åã«ãã€ãŠçæã
ããã©ã°ã¡ã³ããããã®åŸã®æ€å®ã«ãšã€ãŠå°ãã
ããããã§ãããã©ã®ãããªå Žåã§ãããã®ãã
ãªå°ããªã¿ã³ãã¯è³ªã®ãæ¬çºæã®æ¹æ³ã«ããæ€å®
ã«å¯Ÿããé©æ§ã¯ç°¡åãªäºåå®éšã§æ±ºå®ã§ãããæ¬
çºæã®æ¹æ³ã¯ã¿ã³ãã¯è³ªå šååã®æ€å®ã ãã§ãªã
ã¿ã³ãã¯è³ªãã©ã°ã¡ã³ãã®æ€å®ã«ãå¿çšã§ããã
ãªã³ïŒ¥ïŒIgEïŒã®æ€å®ã«ç¹ã«æçšã§ããããä»ã®
å ç«ã°ãããªã³ãä»ã®ã¿ã³ãã¯è³ªäŸãã°TSHïŒç²
ç¶è ºåºæ¿ãã«ã¢ã³ïŒãåµå·£åºæ¿ãã«ã¢ã³ïŒFSHïŒ
ããã³ããæé·ãã«ã¢ã³ïŒHGHïŒã«ã䜿ããã
ãããã®ã¿ã³ãã¯è³ªã¯ãã¹ãŠæ¯èŒç倧ããªååé
ïŒäŸãã°ååé50000以äžïŒãæã€æ¯èŒçå°ããªã¿
ã³ãã¯è³ªäŸãã°ã€ã³ã·ãŠãªã³ãã¢ã³ãžãªãã³ã·ã³
ããã³ã¯ãæ¬çºææ¹æ³ã«ããæ€å®ãããå°é£
ã§ãããããã¯ã液äœè©Šæã®æ¶åã«ãã€ãŠçæã
ããã©ã°ã¡ã³ããããã®åŸã®æ€å®ã«ãšã€ãŠå°ãã
ããããã§ãããã©ã®ãããªå Žåã§ãããã®ãã
ãªå°ããªã¿ã³ãã¯è³ªã®ãæ¬çºæã®æ¹æ³ã«ããæ€å®
ã«å¯Ÿããé©æ§ã¯ç°¡åãªäºåå®éšã§æ±ºå®ã§ãããæ¬
çºæã®æ¹æ³ã¯ã¿ã³ãã¯è³ªå šååã®æ€å®ã ãã§ãªã
ã¿ã³ãã¯è³ªãã©ã°ã¡ã³ãã®æ€å®ã«ãå¿çšã§ããã
æ¬çºææ¹æ³ã«ãããŠã¯ãæ¶åæžæ··åç©äžã§å¯Ÿè±¡
ã¿ã³ãã¯è³ªãç¹å®ããæåæ§æ±ºå®å åãæ€å®ã
ããåèšã®ããã«ããã®æåæ§æ±ºå®å åã¯ã¿ã³ã
ã¯è³ªã®å šååã§ããããšããå šååããçæãã
ç¹å®çãªãã©ã°ã¡ã³ãã§ããããšããããå€ãã®
ç°ãªãæ€å®æ¹æ³ã䜿ãããåŸã«ããããèšèŒãã
ã©ããã¯ã¹ç²åæ€å®ã䜿ãã®ã奜ãŸãããå€ãã®
å Žåã«éåžžã«æå©ãªæ¹æ³ã§ããããäžå¯æ¬ ãªãã®
ã§ã¯ãªããäŸãã°æ¬¡ã®ãããªä»ã®æ¹æ³ã䜿ããã
ã¿ã³ãã¯è³ªãç¹å®ããæåæ§æ±ºå®å åãæ€å®ã
ããåèšã®ããã«ããã®æåæ§æ±ºå®å åã¯ã¿ã³ã
ã¯è³ªã®å šååã§ããããšããå šååããçæãã
ç¹å®çãªãã©ã°ã¡ã³ãã§ããããšããããå€ãã®
ç°ãªãæ€å®æ¹æ³ã䜿ãããåŸã«ããããèšèŒãã
ã©ããã¯ã¹ç²åæ€å®ã䜿ãã®ã奜ãŸãããå€ãã®
å Žåã«éåžžã«æå©ãªæ¹æ³ã§ããããäžå¯æ¬ ãªãã®
ã§ã¯ãªããäŸãã°æ¬¡ã®ãããªä»ã®æ¹æ³ã䜿ããã
(a) æåæ§æ±ºå®å åïŒãŸãã¯ä»ã®éžæççµåç©
質ïŒã®ãäŸãã°ç®¡å£ã«åºå®ãããŠãããã®ã®äœ¿
çšã
質ïŒã®ãäŸãã°ç®¡å£ã«åºå®ãããŠãããã®ã®äœ¿
çšã
(b) æŸå°èœã§ã©ãã«ããç©è³ªããã³æäœã䜿ã€ã
ã©ãžãªã€ã ãã¢ãã»ã€ã
ã©ãžãªã€ã ãã¢ãã»ã€ã
(c) æŸå°èœã§ã©ãã«ããæäœã䜿ã€ãã©ãžãªã€ã
ãã¢ãã»ã€ã
ãã¢ãã»ã€ã
(d) ã©ãã«ãäŸãã°ã±ã€å
ã©ãã«ãé
µçŽ ã©ãã«ãŸ
ãã¯ååŠçºå ã©ãã«ã䜿ãä»ã®å ¬ç¥ã®æ€å®æ³ã
ãã¯ååŠçºå ã©ãã«ã䜿ãä»ã®å ¬ç¥ã®æ€å®æ³ã
ãããã®ãŸãä»ã®æè¡ã¯åœåéã§ã¯å
¬ç¥ã®äºã§
ããããããã«ã¯è©³è¿°ããªãã
ããããããã«ã¯è©³è¿°ããªãã
æ€å®å¯Ÿè±¡ã¿ã³ãã¯è³ªãç¹å®ããæåæ§æ±ºå®å å
ã枬å®ããæ¬çºæã®æ€å®æ®µéã§ã¯ãåèšæ±ºå®å å
ãæäœãšåå¿ãããã®ã奜ãŸããã奜ãŸããã¯ã
åèšæ±ºå®å åã«å¯ŸããŠç¹ç°çã«æäœãç£çããŠã
ããåŸã€ãŠäŸãã°å¯Ÿè±¡ã¿ã³ãã¯è³ªããã©ã°ã¡ã³ã
åããå Žåã¯ç¹å®æ§ãã©ã°ã¡ã³ãã«å¯Ÿããæäœã
ç£çãããã®æäœã䜿ã€ãŠãã©ã°ã¡ã³ãã®æ€å®ã
è¡ãªãã®ã奜ãŸããã(c)ãã©ã°ã¡ã³ããååšã
ãªãå Žåã¯æäœå šäœãããŸãã¯æäœå šäœãååšã
ãªãå Žåã¯ïŒŠïŒabïŒãã©ã°ã¡ã³ãäŸãã°ïŒŠïŒabâ²ïŒ2
ãã©ã°ã¡ã³ãã䜿ããïŒãã¯ãã³ã³ã»ã€ã³ã¹ãã«
ã¡ã³ã瀟ã®è±åœç¹èš±ç¬¬2013688å·åç §ïŒãããã§
ãæäœã®ïŒŠïŒabïŒé åããªãèªã䜿ãå Žåã¯å®å š
ãªæäœå šäœããã®ïŒŠïŒabïŒé åãããŸãã¯æäœã®
(c)éšåããåé¢ããïŒabïŒãã©ã°ã¡ã³ããäŸ
ãã°ïŒŠïŒabâ²ïŒ2ãã®ãããããæå³ããã以äžã«ã
ããŠæäœã®äœ¿çšã«ã€ããŠã®èšèŒã¯ãæäœå šäœã®äœ¿
çšããã³æäœã®ïŒŠïŒabïŒãã©ã°ã¡ã³ãã®äœ¿çšã«ã€
ããŠã®èšèŒãå«ããã®ãšããã
ã枬å®ããæ¬çºæã®æ€å®æ®µéã§ã¯ãåèšæ±ºå®å å
ãæäœãšåå¿ãããã®ã奜ãŸããã奜ãŸããã¯ã
åèšæ±ºå®å åã«å¯ŸããŠç¹ç°çã«æäœãç£çããŠã
ããåŸã€ãŠäŸãã°å¯Ÿè±¡ã¿ã³ãã¯è³ªããã©ã°ã¡ã³ã
åããå Žåã¯ç¹å®æ§ãã©ã°ã¡ã³ãã«å¯Ÿããæäœã
ç£çãããã®æäœã䜿ã€ãŠãã©ã°ã¡ã³ãã®æ€å®ã
è¡ãªãã®ã奜ãŸããã(c)ãã©ã°ã¡ã³ããååšã
ãªãå Žåã¯æäœå šäœãããŸãã¯æäœå šäœãååšã
ãªãå Žåã¯ïŒŠïŒabïŒãã©ã°ã¡ã³ãäŸãã°ïŒŠïŒabâ²ïŒ2
ãã©ã°ã¡ã³ãã䜿ããïŒãã¯ãã³ã³ã»ã€ã³ã¹ãã«
ã¡ã³ã瀟ã®è±åœç¹èš±ç¬¬2013688å·åç §ïŒãããã§
ãæäœã®ïŒŠïŒabïŒé åããªãèªã䜿ãå Žåã¯å®å š
ãªæäœå šäœããã®ïŒŠïŒabïŒé åãããŸãã¯æäœã®
(c)éšåããåé¢ããïŒabïŒãã©ã°ã¡ã³ããäŸ
ãã°ïŒŠïŒabâ²ïŒ2ãã®ãããããæå³ããã以äžã«ã
ããŠæäœã®äœ¿çšã«ã€ããŠã®èšèŒã¯ãæäœå šäœã®äœ¿
çšããã³æäœã®ïŒŠïŒabïŒãã©ã°ã¡ã³ãã®äœ¿çšã«ã€
ããŠã®èšèŒãå«ããã®ãšããã
æ¬çºææ¹æ³ã®å¥œãŸããæ€å®æè¡ã¯ã©ããã¯ã¹ç²
ååéæè¡ã§ãããæ°çš®é¡ã®ãã®ãããªæè¡ãã
ããããããã¯ãã¹ãŠåœåéã§å ¬ç¥ã§ããããå ¬
ç¥ã«ãªãã€ã€ããããããã®äžã§å¥œãŸãã®ã¯ä»¥äž
ã®ãã®ã§ããã
ååéæè¡ã§ãããæ°çš®é¡ã®ãã®ãããªæè¡ãã
ããããããã¯ãã¹ãŠåœåéã§å ¬ç¥ã§ããããå ¬
ç¥ã«ãªãã€ã€ããããããã®äžã§å¥œãŸãã®ã¯ä»¥äž
ã®ãã®ã§ããã
(a) æ€å®å¯Ÿè±¡ã®æåæ§æ±ºå®å åãå«ãæ¶åå€æ··å
ç©ããåèšæ±ºå®å åäŸãã°ç¹å®æ§ãã©ã°ã¡ã³ã
ã«å¯Ÿããæäœãä¿æããŠããã©ããã¯ã¹ç²åãš
æ··åãããæåæ§æ±ºå®å åã®éã«å¿ããçšåºŠã«
åéãèµ·ãããåéã®çšåºŠãçŽæ¥ãããŸãã¯ã
ã奜ãŸããã¯éåéã©ããã¯ã¹ç²åãèšæ°ãã
ããšã«ãã枬å®ããã
ç©ããåèšæ±ºå®å åäŸãã°ç¹å®æ§ãã©ã°ã¡ã³ã
ã«å¯Ÿããæäœãä¿æããŠããã©ããã¯ã¹ç²åãš
æ··åãããæåæ§æ±ºå®å åã®éã«å¿ããçšåºŠã«
åéãèµ·ãããåéã®çšåºŠãçŽæ¥ãããŸãã¯ã
ã奜ãŸããã¯éåéã©ããã¯ã¹ç²åãèšæ°ãã
ããšã«ãã枬å®ããã
(b) æåæ§æ±ºå®å åãå«ãæ¶åå€æ··åç©ãïŒæ±ºå®
å åã«å¯ŸããïŒæäœãšæ··åããŠãæäœïŒæåè€
åäœãã圢æãããIgGã§ã³ãŒãã€ã³ã°ããã©
ããã¯ã¹ç²åãšè€åäœãšãæ··åããããã«åé
å åäŸãã°RFãŸãã¯ããŠã¹è¡æž åéå å
ïŒMAGïŒãç¹å®ã®éå ãããç²åãšè€åäœãš
ã¯åéå åã«ãããŠæ®æãããåéã®çšåºŠã枬
å®ãããšããšã®è©Šæäžã®æåæ§æ±ºå®å åã®éã®
æ€å®ãã§ããã
å åã«å¯ŸããïŒæäœãšæ··åããŠãæäœïŒæåè€
åäœãã圢æãããIgGã§ã³ãŒãã€ã³ã°ããã©
ããã¯ã¹ç²åãšè€åäœãšãæ··åããããã«åé
å åäŸãã°RFãŸãã¯ããŠã¹è¡æž åéå å
ïŒMAGïŒãç¹å®ã®éå ãããç²åãšè€åäœãš
ã¯åéå åã«ãããŠæ®æãããåéã®çšåºŠã枬
å®ãããšããšã®è©Šæäžã®æåæ§æ±ºå®å åã®éã®
æ€å®ãã§ããã
(c) æåæ§æ±ºå®å åãå«ãæ¶åå€æ··åç©ãšãåã
æåæ§æ±ºå®å åãä¿æããŠããã©ããã¯ã¹ç²å
ãšç¹å®ã®éã®åèšæåæ§æ±ºå®å åã«å¯Ÿããæäœ
ãšãæ··åãããç²åãšãéé¢ã®æåæ§æ±ºå®å å
ãšããç¹å®ã®éã®æäœã«ãããŠæ®æãããåé
å åäŸãã°RFãŸãã¯MAGã次ã«å ãããšã
æäœãçµåããŠããç²åã®åéãèµ·ãããåé
ã®çšåºŠã枬å®ãããšãããšã®è©Šæäžã®æåæ§æ±º
å®å åã®éã®æ€å®ãã§ããã
æåæ§æ±ºå®å åãä¿æããŠããã©ããã¯ã¹ç²å
ãšç¹å®ã®éã®åèšæåæ§æ±ºå®å åã«å¯Ÿããæäœ
ãšãæ··åãããç²åãšãéé¢ã®æåæ§æ±ºå®å å
ãšããç¹å®ã®éã®æäœã«ãããŠæ®æãããåé
å åäŸãã°RFãŸãã¯MAGã次ã«å ãããšã
æäœãçµåããŠããç²åã®åéãèµ·ãããåé
ã®çšåºŠã枬å®ãããšãããšã®è©Šæäžã®æåæ§æ±º
å®å åã®éã®æ€å®ãã§ããã
(d) æåæ§æ±ºå®å åãå«ãæ¶åå€æ··åç©ãšãåã
æåæ§æ±ºå®å åãä¿æããŠããã©ããã¯ã¹ç²å
ãšãåèšæåæ§æ±ºå®å åã«å¯Ÿããæäœãä¿æã
ãŠããããå°ããã©ããã¯ã¹ç²åãšãæ··åã
ããéé¢ã®æåæ§æ±ºå®å åã¯ãããïŒçš®é¡ã®ç²
åã®åéãé»å®³ãããåéã®çšåºŠã枬å®ãã
ãšãããšã®è©Šæäžã®æåæ§æ±ºå®å åã®éã®æ€å®
ãã§ããã
æåæ§æ±ºå®å åãä¿æããŠããã©ããã¯ã¹ç²å
ãšãåèšæåæ§æ±ºå®å åã«å¯Ÿããæäœãä¿æã
ãŠããããå°ããã©ããã¯ã¹ç²åãšãæ··åã
ããéé¢ã®æåæ§æ±ºå®å åã¯ãããïŒçš®é¡ã®ç²
åã®åéãé»å®³ãããåéã®çšåºŠã枬å®ãã
ãšãããšã®è©Šæäžã®æåæ§æ±ºå®å åã®éã®æ€å®
ãã§ããã
ãããã®ãã¹ãŠã®æè¡ã«ãããŠãæ¢ç¥éã®æå
æ§æ±ºå®å åãããªãã¡å¯Ÿè±¡ã¿ã³ãã¯è³ªå šååããŸ
ãã¯æ¢ç¥éã®ç¹å®ã®ã¿ã³ãã¯è³ªããã³ã³ãããŒã«
ãããæ¡ä»¶äžã§èªå°ããããã®å¯Ÿè±¡ã¿ã³ãã¯è³ªã®
æåç¹å®æ§ãã©ã°ã¡ã³ããå«ãè©Šæã«ã€ããŠè©Šéš
ãè¡ãªã€ãŠåŸãæšæºå€ãå©çšãããäžè¬çãªæè¡
ã®è©³çŽ°ã«ã€ããŠã¯ãCambiasoçã®J.Immunol.
Methods 23ïŒ29ïŒ1977ïŒã«èšèŒããããåèšã®
æ€å®ã®ãã¡å€§éšåã®æ¹æ³ã§ã¯ãæäœå šäœã®ä»£ãã
ã«ãã®ïŒŠïŒabïŒãã©ã°ã¡ã³ãäŸãã°ïŒŠïŒabâ²ïŒ2ãã©
ã°ã¡ã³ãã䜿ãã®ã奜ãŸããããã®ããšã«ã€ããŠ
ã¯ãã¯ãã³ã³ã»ã€ã³ã¹ãã«ã¡ã³ã瀟ã®è±åœç¹èš±ç¬¬
2013688å·æ现æžã«èšèŒãããã
æ§æ±ºå®å åãããªãã¡å¯Ÿè±¡ã¿ã³ãã¯è³ªå šååããŸ
ãã¯æ¢ç¥éã®ç¹å®ã®ã¿ã³ãã¯è³ªããã³ã³ãããŒã«
ãããæ¡ä»¶äžã§èªå°ããããã®å¯Ÿè±¡ã¿ã³ãã¯è³ªã®
æåç¹å®æ§ãã©ã°ã¡ã³ããå«ãè©Šæã«ã€ããŠè©Šéš
ãè¡ãªã€ãŠåŸãæšæºå€ãå©çšãããäžè¬çãªæè¡
ã®è©³çŽ°ã«ã€ããŠã¯ãCambiasoçã®J.Immunol.
Methods 23ïŒ29ïŒ1977ïŒã«èšèŒããããåèšã®
æ€å®ã®ãã¡å€§éšåã®æ¹æ³ã§ã¯ãæäœå šäœã®ä»£ãã
ã«ãã®ïŒŠïŒabïŒãã©ã°ã¡ã³ãäŸãã°ïŒŠïŒabâ²ïŒ2ãã©
ã°ã¡ã³ãã䜿ãã®ã奜ãŸããããã®ããšã«ã€ããŠ
ã¯ãã¯ãã³ã³ã»ã€ã³ã¹ãã«ã¡ã³ã瀟ã®è±åœç¹èš±ç¬¬
2013688å·æ现æžã«èšèŒãããã
åšç¥ã®ããã«IgEã¯ã¢ã¬ã«ã®ãŒæ§åå¿ã«é¢äžã
ãå ç«ã°ãããªã³ã§ãããç¹å®ã®ã¢ã¬ã«ã®ãŒã«å¯Ÿ
ããããè¡æž äžã®IgEæäœã®ååšã¯åèšã¢ã¬ã«ã²
ã³ã«å¯ŸããŠã¢ã¬ã«ã®ãŒæ§åå¿ãèµ·ããããšã瀺
ãããããŠåèšæäœã®éã¯ã¢ã¬ã«ã®ãŒæ§åå¿ã®åŒ·
床ã瀺ãïŒã€ã®èŠæºãšãªããç¹å®ã®IgEãéçã«
枬å®ã§ãããšããããšã¯ãäŸãã°æ£è ãããè¬ã«
察ããŠã¢ã¬ã«ã®ãŒæ§åå¿ãèµ·ãããã©ãããè©äŸ¡
ããããã«éèŠã§ããããŸããè¡æž äžã«ååšãã
IgEã®ç·éïŒããªãã¡ã皮皮ã®ç¹ç°æ§ãæã€IgE
æäœã®ãã¹ãŠã®åèšïŒã枬å®ã§ãããšããããšã
éèŠã§ãããããããããè¡æž äžã«ååšããIgE
ã®ç·éã¯éåžžã«å°éã§ããããããŠã©ã®ãããªç¹
å®ã®IgEæäœãçè·¡éããååšããªããã®ã§ã
ããåŸã€ãŠéåžžã«éæãªè©Šéšæè¡ãå¿ èŠã§ããã
ãããŠåèšã®åã®ã¿ã³ãã¯è³ªã«ããå¹²æžã¯é倧ãª
ãã®ãšèããããã
ãå ç«ã°ãããªã³ã§ãããç¹å®ã®ã¢ã¬ã«ã®ãŒã«å¯Ÿ
ããããè¡æž äžã®IgEæäœã®ååšã¯åèšã¢ã¬ã«ã²
ã³ã«å¯ŸããŠã¢ã¬ã«ã®ãŒæ§åå¿ãèµ·ããããšã瀺
ãããããŠåèšæäœã®éã¯ã¢ã¬ã«ã®ãŒæ§åå¿ã®åŒ·
床ã瀺ãïŒã€ã®èŠæºãšãªããç¹å®ã®IgEãéçã«
枬å®ã§ãããšããããšã¯ãäŸãã°æ£è ãããè¬ã«
察ããŠã¢ã¬ã«ã®ãŒæ§åå¿ãèµ·ãããã©ãããè©äŸ¡
ããããã«éèŠã§ããããŸããè¡æž äžã«ååšãã
IgEã®ç·éïŒããªãã¡ã皮皮ã®ç¹ç°æ§ãæã€IgE
æäœã®ãã¹ãŠã®åèšïŒã枬å®ã§ãããšããããšã
éèŠã§ãããããããããè¡æž äžã«ååšããIgE
ã®ç·éã¯éåžžã«å°éã§ããããããŠã©ã®ãããªç¹
å®ã®IgEæäœãçè·¡éããååšããªããã®ã§ã
ããåŸã€ãŠéåžžã«éæãªè©Šéšæè¡ãå¿ èŠã§ããã
ãããŠåèšã®åã®ã¿ã³ãã¯è³ªã«ããå¹²æžã¯é倧ãª
ãã®ãšèããããã
è¡æž
äžã®ç¹å®ã®IgEã®ååšããã³ãã®éã確èª
ããããã«è¿å¹Žäœ¿çšãããŠããäž»èŠãªè©Šéšã¯ãã
ããRASTè©Šéšãã©ãžãªã¢ã¬ã«ãŽãœã«ãã³ãã
ã¹ãïŒradioallrgosolbent testïŒããšåŒã°ããã
ãã®è©Šéšã«ãããŠã¯è¡æž ãŸãã¯è¡æ¶²è©Šæãé©åœãª
ã¢ã¬ã«ã²ã³ãæ æããŠããåžåå€ãã€ã¹ã¯ãšæ¥è§Š
ãããŠçœ®ãããã®ã¢ã¬ã«ã²ã³ã«å¯ŸããIgEæäœã¯
ïŒãããããããã°ïŒãã€ã¹ã¯äžã§ã¢ã¬ã«ã²ã³ãš
çµåããã次ã«ãã€ã¹ã¯ãæŽãããããŠãããã
çµåããIgEã125Iæšèä»ãããIgEæäœã䜿çšã
ãŠèšæž¬ãããåèšè©Šéšã¯ïŒåããšã«24æéãã
ãããããŠæŸå°èœæšèIgEã®äœ¿çšã®ããããªãèŠ
åŽãå€ããŠé«äŸ¡ã§ããã
ããããã«è¿å¹Žäœ¿çšãããŠããäž»èŠãªè©Šéšã¯ãã
ããRASTè©Šéšãã©ãžãªã¢ã¬ã«ãŽãœã«ãã³ãã
ã¹ãïŒradioallrgosolbent testïŒããšåŒã°ããã
ãã®è©Šéšã«ãããŠã¯è¡æž ãŸãã¯è¡æ¶²è©Šæãé©åœãª
ã¢ã¬ã«ã²ã³ãæ æããŠããåžåå€ãã€ã¹ã¯ãšæ¥è§Š
ãããŠçœ®ãããã®ã¢ã¬ã«ã²ã³ã«å¯ŸããIgEæäœã¯
ïŒãããããããã°ïŒãã€ã¹ã¯äžã§ã¢ã¬ã«ã²ã³ãš
çµåããã次ã«ãã€ã¹ã¯ãæŽãããããŠãããã
çµåããIgEã125Iæšèä»ãããIgEæäœã䜿çšã
ãŠèšæž¬ãããåèšè©Šéšã¯ïŒåããšã«24æéãã
ãããããŠæŸå°èœæšèIgEã®äœ¿çšã®ããããªãèŠ
åŽãå€ããŠé«äŸ¡ã§ããã
è¿å¹ŽãããŒRASTè©ŠéšãšåŒã°ããå€åããã
RASTè©ŠéšãGleichãã«ããJ.Allergy Clin.
Immunol.ïŒVol 65ïŒNo.ïŒïŒç¬¬20ã28é ïŒ1980幎
ïŒæïŒã«èšèŒãããããã®è©Šéšã«ãããŠã¯ãæ€å®
ããIgEã¯åºçžã¢ã¬ã«ã²ã³ã«ããéžæçã«åžåã
ããã次ã«ãããæ€å®ããIgEã®ïŒŠ(c)ãã©ã°ã¡ã³
ãã«å¯ŸããŠåå¿ããæŸå°èœæšèæè¡æž ã䜿çšããŠ
æ€å®ããããã©ã°ã¡ã³ãã¯IgEãå解ããããã®
ããã·ã³ã®äœ¿çšã«ãã圢æãããã䜿çšããæè¡
æž ãIgEå šéšã«å¯ŸããŠåå¿ããããã«ç£çããã
ã®ã§ã¯ãªãïŒïŒã€ã®äœçœ®ã®ã¿ã§IgEãå解ããïŒ
ããã·ã³ã«ããçããç¹ç°çãªïŒŠ(c)ãã©ã°ã¡ã³ã
ã«å¯ŸããŠåå¿ããããã«ç£çããããšãé€ããŠã¯
ãã®æ¹æ³ã¯ç°¡äŸ¿ãªãã®ã§ãããšããããšã«æ³šæã
ã¹ãã§ããã
RASTè©ŠéšãGleichãã«ããJ.Allergy Clin.
Immunol.ïŒVol 65ïŒNo.ïŒïŒç¬¬20ã28é ïŒ1980幎
ïŒæïŒã«èšèŒãããããã®è©Šéšã«ãããŠã¯ãæ€å®
ããIgEã¯åºçžã¢ã¬ã«ã²ã³ã«ããéžæçã«åžåã
ããã次ã«ãããæ€å®ããIgEã®ïŒŠ(c)ãã©ã°ã¡ã³
ãã«å¯ŸããŠåå¿ããæŸå°èœæšèæè¡æž ã䜿çšããŠ
æ€å®ããããã©ã°ã¡ã³ãã¯IgEãå解ããããã®
ããã·ã³ã®äœ¿çšã«ãã圢æãããã䜿çšããæè¡
æž ãIgEå šéšã«å¯ŸããŠåå¿ããããã«ç£çããã
ã®ã§ã¯ãªãïŒïŒã€ã®äœçœ®ã®ã¿ã§IgEãå解ããïŒ
ããã·ã³ã«ããçããç¹ç°çãªïŒŠ(c)ãã©ã°ã¡ã³ã
ã«å¯ŸããŠåå¿ããããã«ç£çããããšãé€ããŠã¯
ãã®æ¹æ³ã¯ç°¡äŸ¿ãªãã®ã§ãããšããããšã«æ³šæã
ã¹ãã§ããã
æ¬çºæã®å¥œãŸããå
·äœçäŸã«ãããŠã¯ã
RASTè©Šéšãå€åãããŠããã€ã¹ã¯ãšãããã¢
ãŒãŒãšãæ¥è§ŠãããçµåããIgEãæ¶åãããã
ãã©ã°ã¡ã³ãã¯IgEã®æåç¹å®æ§ãšãªãããã«è£œ
é ãããããŠãã®ãã©ã°ã¡ã³ãã次ã«éçã«æ€å®
ããããã®æ¶åæè¡ã¯ãã€ã¹ã¯ããã®ååã®ç²Ÿå¯
床ããã³åçŸæ§ã倧ããæ¹è¯ããåŸã€ãŠè©Šéšæ¹æ³
ã®æ床ããã³ä¿¡é ŒåºŠãå¢å ããã
RASTè©Šéšãå€åãããŠããã€ã¹ã¯ãšãããã¢
ãŒãŒãšãæ¥è§ŠãããçµåããIgEãæ¶åãããã
ãã©ã°ã¡ã³ãã¯IgEã®æåç¹å®æ§ãšãªãããã«è£œ
é ãããããŠãã®ãã©ã°ã¡ã³ãã次ã«éçã«æ€å®
ããããã®æ¶åæè¡ã¯ãã€ã¹ã¯ããã®ååã®ç²Ÿå¯
床ããã³åçŸæ§ã倧ããæ¹è¯ããåŸã€ãŠè©Šéšæ¹æ³
ã®æ床ããã³ä¿¡é ŒåºŠãå¢å ããã
åŸã€ãŠæ¬çºæã®å¥ã®èŠ³ç¹ã«ããã°ãæ¬çºæã¯å¯Ÿ
象å€ã®ã¿ã³ãã¯è³ªããã®å¹²æžãæé€ããããŠæ€å®
ã®ç¹ç°æ§ããã³æ£ç¢ºæ§ãæ¹è¯ãã察象å€ã¿ã³ãã¯
質ïŒçš®ãŸãã¯ãã以äžãå«ãçç©åŠçæµåäœäžã®
察象ã¿ã³ãã¯è³ªãæ€å®ããæ¹æ³ãæäŸãããã®æ¹
æ³ã¯ (a) åèšè©Šæãåèšè©Šæäžã®åèšå¯Ÿè±¡ã¿ã³ãã¯è³ª
ã«ã ãéžæçã«çµåããåå¿äœãæ æããäžæŽ»
æ§åºäœæ¯æææãšæ¥è§Šããã (b) è©Šæãã察象ã¿ã³ãã¯è³ªãæ æããåèšæ¯æ
äœææãåãåºãã (c) åèšã®åãåºãã察象ã¿ã³ãã¯è³ªãã察象ã¿
ã³ãã¯è³ªã®æåç¹å®æ§ãã©ã°ã¡ã³ãã圢æãã
æ¡ä»¶äžã§åèšã®åãåºãã察象ã¿ã³ãã¯è³ªãæ¶
åãããã㊠(d) åèšãã©ã°ã¡ã³ããæ€å®ãããã®çµæãã液
äœè©Šæäžã®å¯Ÿè±¡ã¿ã³ãã¯è³ªã®éã決å®ãã ããšããæãã
象å€ã®ã¿ã³ãã¯è³ªããã®å¹²æžãæé€ããããŠæ€å®
ã®ç¹ç°æ§ããã³æ£ç¢ºæ§ãæ¹è¯ãã察象å€ã¿ã³ãã¯
質ïŒçš®ãŸãã¯ãã以äžãå«ãçç©åŠçæµåäœäžã®
察象ã¿ã³ãã¯è³ªãæ€å®ããæ¹æ³ãæäŸãããã®æ¹
æ³ã¯ (a) åèšè©Šæãåèšè©Šæäžã®åèšå¯Ÿè±¡ã¿ã³ãã¯è³ª
ã«ã ãéžæçã«çµåããåå¿äœãæ æããäžæŽ»
æ§åºäœæ¯æææãšæ¥è§Šããã (b) è©Šæãã察象ã¿ã³ãã¯è³ªãæ æããåèšæ¯æ
äœææãåãåºãã (c) åèšã®åãåºãã察象ã¿ã³ãã¯è³ªãã察象ã¿
ã³ãã¯è³ªã®æåç¹å®æ§ãã©ã°ã¡ã³ãã圢æãã
æ¡ä»¶äžã§åèšã®åãåºãã察象ã¿ã³ãã¯è³ªãæ¶
åãããã㊠(d) åèšãã©ã°ã¡ã³ããæ€å®ãããã®çµæãã液
äœè©Šæäžã®å¯Ÿè±¡ã¿ã³ãã¯è³ªã®éã決å®ãã ããšããæãã
ãã®æ¹æ³ã®äŸã¯æ¬¡ã®ããã§ãããè¡æž
è©Šæ
ïŒ50ÎŒïŒã宀枩ã§ïŒæéã¢ã¬ã«ã²ã³ã³ãŒãã€ã³
ã°ããããŒããŒãã€ã¹ã¯ïŒPharmacia UppsalaïŒ
SwedenïŒãšãšãã«ã€ã³ããŠããŒããããççé£
å¡©æ°Žã§ïŒåæŽã€ãåŸããã®ãã€ã¹ã¯ã宀枩ã§ïŒå
éããã·ã³ïŒmgïŒmlãå«ã0.15NHCl 150ÎŒãš
ãšãã«ã€ã³ããŠããŒãããã次ã«2Mããªã¹ïŒã
ãããã·ã¡ãã«ïŒã¡ãã«ã¢ãã³ïŒãTRISãïŒ30ÎŒ
ã®æ·»å ã«ããæ¶åãåæ¢ãããIgEã®æåç¹å®
æ§ã®ããã·ã³æµææ§ãã©ã°ã¡ã³ãã次ã«åèšã®ã©
ããã¯ã¹ç²åæ³ã«ãã決å®ããããã®ããã·ã³æº¶
é¢æ³ã«ããåŸãããçµæãšå ¬ç¥ã®RASTæ³ã«ã
ãåŸãããçµæãšãæ·»ä»å³é¢ã«ç€ºãããã®äžã§ã ïŒãªãªã¢ã¯ã¬ãšãªïŒPhleum pratenseïŒ ïŒ¢ïŒå®¶å¡µã ã«ïŒDermotoph pteronyssïŒ ïŒ£ïŒå®¶å¡µïŒGreerïŒ ïŒ€ïŒå®¶å¡µïŒHollisterâStierïŒ ïŒ¥ïŒãã¯ããªã¹ã°ãã¡ã¬ãŒã¿ïŒDactylis
glomerataïŒ ïŒŠïŒãã³äžç®ïŒCat epitheliumïŒ ïŒ§ïŒã€ãäžç®ïŒDog epitheliumïŒ ïŒšïŒãŠãäžç®ïŒHorse epitheliumïŒ ïŒ©ïŒãªãªãã³ïŒPlantago lanceolateïŒ ïŒªïŒãšã¢ã®ïŒArtemisia vulgarisïŒ ïŒ«ïŒã¯ã©ãã¹ããªãŠã ïŒCladosporium
herbarumïŒ ïŒ¬ïŒçè²éº¹èã±ã ã«ãïŒAspergillus fumigatusïŒ ã§ããã
ïŒ50ÎŒïŒã宀枩ã§ïŒæéã¢ã¬ã«ã²ã³ã³ãŒãã€ã³
ã°ããããŒããŒãã€ã¹ã¯ïŒPharmacia UppsalaïŒ
SwedenïŒãšãšãã«ã€ã³ããŠããŒããããççé£
å¡©æ°Žã§ïŒåæŽã€ãåŸããã®ãã€ã¹ã¯ã宀枩ã§ïŒå
éããã·ã³ïŒmgïŒmlãå«ã0.15NHCl 150ÎŒãš
ãšãã«ã€ã³ããŠããŒãããã次ã«2Mããªã¹ïŒã
ãããã·ã¡ãã«ïŒã¡ãã«ã¢ãã³ïŒãTRISãïŒ30ÎŒ
ã®æ·»å ã«ããæ¶åãåæ¢ãããIgEã®æåç¹å®
æ§ã®ããã·ã³æµææ§ãã©ã°ã¡ã³ãã次ã«åèšã®ã©
ããã¯ã¹ç²åæ³ã«ãã決å®ããããã®ããã·ã³æº¶
é¢æ³ã«ããåŸãããçµæãšå ¬ç¥ã®RASTæ³ã«ã
ãåŸãããçµæãšãæ·»ä»å³é¢ã«ç€ºãããã®äžã§ã ïŒãªãªã¢ã¯ã¬ãšãªïŒPhleum pratenseïŒ ïŒ¢ïŒå®¶å¡µã ã«ïŒDermotoph pteronyssïŒ ïŒ£ïŒå®¶å¡µïŒGreerïŒ ïŒ€ïŒå®¶å¡µïŒHollisterâStierïŒ ïŒ¥ïŒãã¯ããªã¹ã°ãã¡ã¬ãŒã¿ïŒDactylis
glomerataïŒ ïŒŠïŒãã³äžç®ïŒCat epitheliumïŒ ïŒ§ïŒã€ãäžç®ïŒDog epitheliumïŒ ïŒšïŒãŠãäžç®ïŒHorse epitheliumïŒ ïŒ©ïŒãªãªãã³ïŒPlantago lanceolateïŒ ïŒªïŒãšã¢ã®ïŒArtemisia vulgarisïŒ ïŒ«ïŒã¯ã©ãã¹ããªãŠã ïŒCladosporium
herbarumïŒ ïŒ¬ïŒçè²éº¹èã±ã ã«ãïŒAspergillus fumigatusïŒ ã§ããã
ãã®å€æ§RASTæ€å®æ³ã¯ç¹å®ã®IgEæäœãæ€å®
ããããã®æ¬çºæã®æ¹æ³ã®å¥œãŸããäžè¬çæ¹æ³ã®
äžäŸã«ãããããªããšããããšãç解ããããã
ããªãã¡ã第ïŒã«æ€å®å¯Ÿè±¡ã®ç¹å®ã®IgEãä»ã«å
åšããIgEããåé¢ãããããŠæ¬¡ã«IgEãé µçŽ ç
ã«æ¶åããããŠãã©ã°ã¡ã³ããæ€å®ããããã¡ã
ãè©Šæäžã®IgEã®ç·éããæ¬çºæã«ããç°¡åãªã
ãã·ã³æ¶åããã³ã²ãã€ã¥ãIgEã®ç·éã«å¯ŸããŠ
ç¹å®çãªãã©ã°ã¡ã³ãã®æ€å®ãè¡ãããšã«ããæ€
å®ããããšãã§ããããããïŒã€ã®æ¹æ³ïŒç¹å®ã®
IgEã®æ€å®ããã³ç·IgEã®æ€å®ïŒã«ãããŠã¯åäž
ã®æäœã䜿çšã§ãããã®ãã®ã¯IgEå šäœã®ç¹åŸŽã
瀺ããã©ã°ã¡ã³ãã«å¯ŸããŠç£çãããæäœã§ã
ãããã¡ããåèšæäœã¯ä»»æã®IgEã®æ¶åã«ãã
圢æããåèšãã©ã°ã¡ã³ããšçµåãããåèšã®å€
æ§RASTæ³ã«ãããŠæ€å®ã®éžææ§ã¯ã第ïŒã«ä»
ã®IgEãšã®æ··åç©ããç¹å®ã®IgEãåé¢ããããš
ã«ããéæãããããã¹ãŠã®IgEæ€å®ã«å¯ŸããŠïŒ
çš®é¡ã®æäœã®ã¿äœ¿çšãããã®æè¡ã¯éåžžã«å¥œãŸã
ãããšããã®ã¯å°ããšãçè«äžååã®IgEæäœã®
æåç¹å®æ§ãã©ã°ã¡ã³ãã«å¯Ÿããæäœã補é ãã
ããšã¯å¯èœã§ããããã©ãããã®ãããªæŽ»æ§ïŒæ
åç¹å®æ§ïŒãã©ã°ã¡ã³ãã¯ãããã®æºïŒäŸãã°ã
ã©ã°ã¡ã³ããåŸãç¹å®ã®ããã®ç¹æ§ã瀺ãåŸåã«
ãããããç°ã人éããåŸãåäžã®IgEã®æ€å®ã«
ãããŠäœ¿ãããšã«ã¯å©çããªãããã§ããã
ããããã®æ¬çºæã®æ¹æ³ã®å¥œãŸããäžè¬çæ¹æ³ã®
äžäŸã«ãããããªããšããããšãç解ããããã
ããªãã¡ã第ïŒã«æ€å®å¯Ÿè±¡ã®ç¹å®ã®IgEãä»ã«å
åšããIgEããåé¢ãããããŠæ¬¡ã«IgEãé µçŽ ç
ã«æ¶åããããŠãã©ã°ã¡ã³ããæ€å®ããããã¡ã
ãè©Šæäžã®IgEã®ç·éããæ¬çºæã«ããç°¡åãªã
ãã·ã³æ¶åããã³ã²ãã€ã¥ãIgEã®ç·éã«å¯ŸããŠ
ç¹å®çãªãã©ã°ã¡ã³ãã®æ€å®ãè¡ãããšã«ããæ€
å®ããããšãã§ããããããïŒã€ã®æ¹æ³ïŒç¹å®ã®
IgEã®æ€å®ããã³ç·IgEã®æ€å®ïŒã«ãããŠã¯åäž
ã®æäœã䜿çšã§ãããã®ãã®ã¯IgEå šäœã®ç¹åŸŽã
瀺ããã©ã°ã¡ã³ãã«å¯ŸããŠç£çãããæäœã§ã
ãããã¡ããåèšæäœã¯ä»»æã®IgEã®æ¶åã«ãã
圢æããåèšãã©ã°ã¡ã³ããšçµåãããåèšã®å€
æ§RASTæ³ã«ãããŠæ€å®ã®éžææ§ã¯ã第ïŒã«ä»
ã®IgEãšã®æ··åç©ããç¹å®ã®IgEãåé¢ããããš
ã«ããéæãããããã¹ãŠã®IgEæ€å®ã«å¯ŸããŠïŒ
çš®é¡ã®æäœã®ã¿äœ¿çšãããã®æè¡ã¯éåžžã«å¥œãŸã
ãããšããã®ã¯å°ããšãçè«äžååã®IgEæäœã®
æåç¹å®æ§ãã©ã°ã¡ã³ãã«å¯Ÿããæäœã補é ãã
ããšã¯å¯èœã§ããããã©ãããã®ãããªæŽ»æ§ïŒæ
åç¹å®æ§ïŒãã©ã°ã¡ã³ãã¯ãããã®æºïŒäŸãã°ã
ã©ã°ã¡ã³ããåŸãç¹å®ã®ããã®ç¹æ§ã瀺ãåŸåã«
ãããããç°ã人éããåŸãåäžã®IgEã®æ€å®ã«
ãããŠäœ¿ãããšã«ã¯å©çããªãããã§ããã
åèšå€æ§RASTæ³ã¯ç¬¬ïŒã«ã¿ã³ãã¯è³ªãåºçž
ã«çµåããããšã«ããäžæº¶æ§ã«ãã次ã«åºçžãé µ
çŽ ãšæ¥è§ŠãããŠã¿ã³ãã¯è³ªãæ¶åããããããç¹
å®æ§ãã©ã°ã¡ã³ããæ€å®ããããšããæãã¿ã³ã
ã¯è³ªãæ€å®ããããã®æ¬çºæã®äžè¬çæè¡ã®äžäŸ
ã§ãããšããããšãç解ãããããããã®å¥ã®äŸ
ã¯ããªããŒãäžã§ã®ç²ç¶è ºåºæ¿ãã«ã¢ã³ïŒTSHïŒ
ã®å®éã§ããïŒH.BickelïŒR.Guthrieããã³G.
HammersenïŒNational Screening for Inborn
Errors of MetabolismïŒBerlinïŒSpringerã第
219ã228é ã1980幎ãåç §ããããïŒãè¡æ¶²è©Šæ
ã¯ãã€ã«ã¿ãŒããŒããŒãã€ã¹ã¯äžã§éããããã
ã®ãã®ã次ã«ä¹Ÿç¥ããŠç 究æãžéããæ¬çºæã«ã
ã也ç¥è¡æ¶²è©Šæã®ããã·ã³æ¶åã«ããå埩ã¯å®¹æ
ã«è¡ããããããŒããŒãã€ã¹ã¯äžã®è¡æ¶²ãéãã
ãã®æ¹æ³ã¯è©Šæã®èŒžéã§å±éºã§ããå ŽåãåŸé²åœ
ã«ãããŠã ãã ãäžè¬çã«ãªã€ãŠããŠããã
ã«çµåããããšã«ããäžæº¶æ§ã«ãã次ã«åºçžãé µ
çŽ ãšæ¥è§ŠãããŠã¿ã³ãã¯è³ªãæ¶åããããããç¹
å®æ§ãã©ã°ã¡ã³ããæ€å®ããããšããæãã¿ã³ã
ã¯è³ªãæ€å®ããããã®æ¬çºæã®äžè¬çæè¡ã®äžäŸ
ã§ãããšããããšãç解ãããããããã®å¥ã®äŸ
ã¯ããªããŒãäžã§ã®ç²ç¶è ºåºæ¿ãã«ã¢ã³ïŒTSHïŒ
ã®å®éã§ããïŒH.BickelïŒR.Guthrieããã³G.
HammersenïŒNational Screening for Inborn
Errors of MetabolismïŒBerlinïŒSpringerã第
219ã228é ã1980幎ãåç §ããããïŒãè¡æ¶²è©Šæ
ã¯ãã€ã«ã¿ãŒããŒããŒãã€ã¹ã¯äžã§éããããã
ã®ãã®ã次ã«ä¹Ÿç¥ããŠç 究æãžéããæ¬çºæã«ã
ã也ç¥è¡æ¶²è©Šæã®ããã·ã³æ¶åã«ããå埩ã¯å®¹æ
ã«è¡ããããããŒããŒãã€ã¹ã¯äžã®è¡æ¶²ãéãã
ãã®æ¹æ³ã¯è©Šæã®èŒžéã§å±éºã§ããå ŽåãåŸé²åœ
ã«ãããŠã ãã ãäžè¬çã«ãªã€ãŠããŠããã
ããã«ãæ€å®ããããã¢ãŒãŒãè±å¯ãªçç©åŠç
æµäœäŸãã°è žæ¶²ãŸãã¯çŽ°èæœåºæ¶²ã«é©çšããªãã
ã°ãªããªãå Žåãå®å šãªã¿ã³ãã¯è³ªååãããã¿
ã³ãã¯è³ªãå解ãããã©ã°ã¡ã³ãã®å®éã®æ¹ãæ
çšã§ãããå¥ã®é©çšã¯çŽ°è質èäžã«æ··åããæå
äŸãã°å¥œå¡©åºæ§èäžã®IgEã®å®éã§ãããæ¶åã¯
èããã®æåã®æœåºã«ãã容æã«è¡ãããã
æµäœäŸãã°è žæ¶²ãŸãã¯çŽ°èæœåºæ¶²ã«é©çšããªãã
ã°ãªããªãå Žåãå®å šãªã¿ã³ãã¯è³ªååãããã¿
ã³ãã¯è³ªãå解ãããã©ã°ã¡ã³ãã®å®éã®æ¹ãæ
çšã§ãããå¥ã®é©çšã¯çŽ°è質èäžã«æ··åããæå
äŸãã°å¥œå¡©åºæ§èäžã®IgEã®å®éã§ãããæ¶åã¯
èããã®æåã®æœåºã«ãã容æã«è¡ãããã
æ¬çºæã®æ¹æ³ã«ãããŠã¯ãRFããã³è£äœå å
ããã®å¹²æžãããŠä»ã®éç¹ç°æ§ã¿ã³ãã¯è³ªâã¿ã³
ãã¯è³ªçžäºäœçšããã®å¹²æžã®å±éºã¯ãããã®ã¿ã³
ãã¯è³ªãæ £ç¿ã«åŸã€ãŠããã·ã³ã®ãããªåèšé µçŽ
ã«ããæ¶åã«ãããããŠããããå®è³ªçã«éåžžã«
æžå°ããŠãããããã«è©Šéšäžã察象ã¿ã³ãã¯è³ªã®
ãã©ã°ã¡ã³ãç¹æ§ãæ€å®ããå Žåãæäœã®äº€ãå
å¿ããã®å¹²æžããŸãæé€ããããäŸãã°ãHGH
ã«å¯Ÿããæè¡æž ã¯ãŸãããèç€ã©ã¯ãã²ã³
ïŒHPLïŒãšäº€ãåå¿ããããšã¯åœæ¥çã«ãšã€ãŠåš
ç¥ã§ããããã®åã®å¹²æžã¯æ¬çºæã®æ¹æ³ã«ããæž
å°ãããã¯æé€ããããå¥ã®äŸã¯FSHããã³LH
ïŒé»äœåãã«ã¢ã³ïŒã§ããããããã¯æäœã«ãã
äºãã«èå¥ããããšã¯ã§ããªããããããããã·
ã³æ¶åã®åŸçæããç°ããã©ã°ã¡ã³ãã¯æäœãšå
å¿ã§ãããã®ããšã«ãããã©ã°ã¡ã³ããèå¥ã§ã
ããéç¹ç°ççžäºäœçšãæé€ããæ¬çºæã®å¹æã®
説æãšããŠæäœã®ïŒŠïŒabâ²ïŒ2ãã©ã°ã¡ã³ãã䜿çš
ããã±ã€ãªãããŒãå€ãšããŠ1Må¡©åãããªãŠã
ã䜿çšããç·IgEã®éåžžã®æ€å®ã«ãããŠã¯çžäºäœ
çšã容èªã§ããäœãçšåºŠãŸã§æžããããã«è¡æž ã
10åã«åžéããå¿ èŠããããšããããšãããã€
ããããããæ¬çºæã®æ¹æ³ã䜿çšããã°è¡æž è©Šæ
ã®åžéã®å¿ èŠã¯ãªããäž¡æ¹ã®å Žåã®æ€å®ã¯åèšã®
ã©ããã¯ã¹ç²åæ³(a)ã«ããè¡ããã䜿çšããé µçŽ
ã¯ããã·ã³ã§ããã
ããã®å¹²æžãããŠä»ã®éç¹ç°æ§ã¿ã³ãã¯è³ªâã¿ã³
ãã¯è³ªçžäºäœçšããã®å¹²æžã®å±éºã¯ãããã®ã¿ã³
ãã¯è³ªãæ £ç¿ã«åŸã€ãŠããã·ã³ã®ãããªåèšé µçŽ
ã«ããæ¶åã«ãããããŠããããå®è³ªçã«éåžžã«
æžå°ããŠãããããã«è©Šéšäžã察象ã¿ã³ãã¯è³ªã®
ãã©ã°ã¡ã³ãç¹æ§ãæ€å®ããå Žåãæäœã®äº€ãå
å¿ããã®å¹²æžããŸãæé€ããããäŸãã°ãHGH
ã«å¯Ÿããæè¡æž ã¯ãŸãããèç€ã©ã¯ãã²ã³
ïŒHPLïŒãšäº€ãåå¿ããããšã¯åœæ¥çã«ãšã€ãŠåš
ç¥ã§ããããã®åã®å¹²æžã¯æ¬çºæã®æ¹æ³ã«ããæž
å°ãããã¯æé€ããããå¥ã®äŸã¯FSHããã³LH
ïŒé»äœåãã«ã¢ã³ïŒã§ããããããã¯æäœã«ãã
äºãã«èå¥ããããšã¯ã§ããªããããããããã·
ã³æ¶åã®åŸçæããç°ããã©ã°ã¡ã³ãã¯æäœãšå
å¿ã§ãããã®ããšã«ãããã©ã°ã¡ã³ããèå¥ã§ã
ããéç¹ç°ççžäºäœçšãæé€ããæ¬çºæã®å¹æã®
説æãšããŠæäœã®ïŒŠïŒabâ²ïŒ2ãã©ã°ã¡ã³ãã䜿çš
ããã±ã€ãªãããŒãå€ãšããŠ1Må¡©åãããªãŠã
ã䜿çšããç·IgEã®éåžžã®æ€å®ã«ãããŠã¯çžäºäœ
çšã容èªã§ããäœãçšåºŠãŸã§æžããããã«è¡æž ã
10åã«åžéããå¿ èŠããããšããããšãããã€
ããããããæ¬çºæã®æ¹æ³ã䜿çšããã°è¡æž è©Šæ
ã®åžéã®å¿ èŠã¯ãªããäž¡æ¹ã®å Žåã®æ€å®ã¯åèšã®
ã©ããã¯ã¹ç²åæ³(a)ã«ããè¡ããã䜿çšããé µçŽ
ã¯ããã·ã³ã§ããã
æ¬çºææ¹æ³ã«ããã°ãæ€å®äžã§ã¿ã³ãã¯è³ªãæ¶
åã«ããæåã«å解ããæã§ããæ€å®ã®æ床ãå
äžãããããšãã§ããããã®çç±ã¯ä»¥äžã®ãšãã
ã§ãããã¿ã³ãã¯è³ªãåç©ã«æ³šå ¥ãããšããã®å
ç©ãç£åºããæäœã¯åœè©²ã¿ã³ãã¯è³ªååã®çš®çš®ã®
é åã瀺ãå€æ°ã®æåæ§æ±ºå®å åã«å¯ŸããŠã®ãã®
ã§ããããããã®æå決å®å åã®äžã«ã¯ãæãã
ãŠããªãïŒå®å šïŒã¿ã³ãã¯è³ªäžã®æäœã«å¯ŸããŠè¿
ã¥ãã«ãããã®ããããããããªãããåç©ã¯æ¥
çš®ãããã¿ã³ãã¯è³ªãçäœçã§éšåæ¶åããããš
ã«ãããåèšã®ãããªé ãã決å®å åã«å¯Ÿããæ
äœãç£çããããšãã§ãããè©Šéšç®¡å ã«ãããŠ
ã¯ãããã·ã³ãŸãã¯ä»ã®ãããã¢ãŒãŒã«ããæ¶å
ã«ãã€ãŠé ããæåæ§æ±ºå®å åãçºçŸããããšã
ã§ããåŸã€ãŠããã決å®å åãç®çãšããæäœã
ããã決å®å åãšã®åå¿ã«å«ããããšãã§ããçµ
æãšããŠæ床ãåäžãåäžãããããšãã§ããã®
ã§ããã
åã«ããæåã«å解ããæã§ããæ€å®ã®æ床ãå
äžãããããšãã§ããããã®çç±ã¯ä»¥äžã®ãšãã
ã§ãããã¿ã³ãã¯è³ªãåç©ã«æ³šå ¥ãããšããã®å
ç©ãç£åºããæäœã¯åœè©²ã¿ã³ãã¯è³ªååã®çš®çš®ã®
é åã瀺ãå€æ°ã®æåæ§æ±ºå®å åã«å¯ŸããŠã®ãã®
ã§ããããããã®æå決å®å åã®äžã«ã¯ãæãã
ãŠããªãïŒå®å šïŒã¿ã³ãã¯è³ªäžã®æäœã«å¯ŸããŠè¿
ã¥ãã«ãããã®ããããããããªãããåç©ã¯æ¥
çš®ãããã¿ã³ãã¯è³ªãçäœçã§éšåæ¶åããããš
ã«ãããåèšã®ãããªé ãã決å®å åã«å¯Ÿããæ
äœãç£çããããšãã§ãããè©Šéšç®¡å ã«ãããŠ
ã¯ãããã·ã³ãŸãã¯ä»ã®ãããã¢ãŒãŒã«ããæ¶å
ã«ãã€ãŠé ããæåæ§æ±ºå®å åãçºçŸããããšã
ã§ããåŸã€ãŠããã決å®å åãç®çãšããæäœã
ããã決å®å åãšã®åå¿ã«å«ããããšãã§ããçµ
æãšããŠæ床ãåäžãåäžãããããšãã§ããã®
ã§ããã
åèšã®æ床åäžã瀺ããã®ãšããŠãæ¬çºæè
ã¯
åèšã®äžè¬ã©ããã¯ã¹ç²åæ€å®æè¡(a)ã䜿ã€ãŠæ¬
çºæã®æ€å®ã®æ床ã0.5ã1.0IUïŒmlã«ãªãã®ãèŠ
ãåºããããªããåæ§ã®æ€å®ïŒãã ãããã·ã³ã«
ããæ¶åãè¡ããªãïŒã«ããæ床ã¯ïŒã10IUïŒ
mlã§ãã€ãã䜿çšããç¹å®ã®æäœæé ã¯ä»¥äžã®ãš
ããã§ãããIgEå«æè©ŠæïŒ50ÎŒïŒãšããã·ã³
ïŒmgïŒmlå«æ0.15Nå¡©é žïŒ150ÎŒïŒãšãæ··åã
ãã宀枩ã§ïŒåéã€ã³ããŠããŒãããŠãã2Mã
ãªã¹ïŒããããã·ã¡ãã«ïŒã¡ãã«ã¢ãã³ïŒ30ÎŒ
ïŒãå ããŠæ¶åãæ¢ããã次ã«IgEãã©ã°ã¡ã³
ããåèšã®ã©ããã¯ã¹ç²åæè¡(a)ã«ãã€ãŠæ€å®ã
ãã
åèšã®äžè¬ã©ããã¯ã¹ç²åæ€å®æè¡(a)ã䜿ã€ãŠæ¬
çºæã®æ€å®ã®æ床ã0.5ã1.0IUïŒmlã«ãªãã®ãèŠ
ãåºããããªããåæ§ã®æ€å®ïŒãã ãããã·ã³ã«
ããæ¶åãè¡ããªãïŒã«ããæ床ã¯ïŒã10IUïŒ
mlã§ãã€ãã䜿çšããç¹å®ã®æäœæé ã¯ä»¥äžã®ãš
ããã§ãããIgEå«æè©ŠæïŒ50ÎŒïŒãšããã·ã³
ïŒmgïŒmlå«æ0.15Nå¡©é žïŒ150ÎŒïŒãšãæ··åã
ãã宀枩ã§ïŒåéã€ã³ããŠããŒãããŠãã2Mã
ãªã¹ïŒããããã·ã¡ãã«ïŒã¡ãã«ã¢ãã³ïŒ30ÎŒ
ïŒãå ããŠæ¶åãæ¢ããã次ã«IgEãã©ã°ã¡ã³
ããåèšã®ã©ããã¯ã¹ç²åæè¡(a)ã«ãã€ãŠæ€å®ã
ãã
ã¿ã³ãã¯è³ªã®å
ç«åŠçæ€å®æ³ã«ãããåŸæ¥æè¡
ã®èª€å·®ã®äžã«ã¯æè¡ããèªäœã«ã§ã¯ãªããæªæ¡ä»¶
äžã§ã®è©Šæã®è²¯èµãŸãã¯èŒžéã«åå ã®ãããã®ã
ãããæ€å®å¯Ÿè±¡ã®ã¿ã³ãã¯è³ªã¯æž©åºŠå€åã«ããã
ããã³è©Šæäžã«ååšããããŸãã¯æ±æãã¯ããªã¢
ããæŸåºããããããã¢ãŒãŒïŒäŸãã°ãã©ãºã
ã³ïŒã«ãã€ãŠå€è³ªãããå¯èœæ§ããããæ¬çºæã«
ãããããã¢ãŒãŒäŸãã°ããã·ã³ã«ããè©Šæã®ç³»
çµ±çåŠçããã³æåæšçãšããŠã®ããããïŒã¿ã³
ãã¯è³ªååå šäœã§ã¯ãªãïŒã®äœ¿çšã¯èª€å·®ã®å±éºã
æžå°ããããããããã¯éåžžãã¿ã³ãã¯è³ªã«æ¯
ã¹ãå€è³ªããã³æŽã«ã¯å解ã«å¯ŸããŠäžå±€æµææ§ã
é«ãã
ã®èª€å·®ã®äžã«ã¯æè¡ããèªäœã«ã§ã¯ãªããæªæ¡ä»¶
äžã§ã®è©Šæã®è²¯èµãŸãã¯èŒžéã«åå ã®ãããã®ã
ãããæ€å®å¯Ÿè±¡ã®ã¿ã³ãã¯è³ªã¯æž©åºŠå€åã«ããã
ããã³è©Šæäžã«ååšããããŸãã¯æ±æãã¯ããªã¢
ããæŸåºããããããã¢ãŒãŒïŒäŸãã°ãã©ãºã
ã³ïŒã«ãã€ãŠå€è³ªãããå¯èœæ§ããããæ¬çºæã«
ãããããã¢ãŒãŒäŸãã°ããã·ã³ã«ããè©Šæã®ç³»
çµ±çåŠçããã³æåæšçãšããŠã®ããããïŒã¿ã³
ãã¯è³ªååå šäœã§ã¯ãªãïŒã®äœ¿çšã¯èª€å·®ã®å±éºã
æžå°ããããããããã¯éåžžãã¿ã³ãã¯è³ªã«æ¯
ã¹ãå€è³ªããã³æŽã«ã¯å解ã«å¯ŸããŠäžå±€æµææ§ã
é«ãã
æ¬çºæãæŽã«è©³çŽ°ã«èª¬æããããã«ä»¥äžã«å®æœ
äŸãèšèŒããããããã¯æ¬çºæã®ç¯å²ãéå®ãã
ãã®ã§ã¯ãªãã
äŸãèšèŒããããããã¯æ¬çºæã®ç¯å²ãéå®ãã
ãã®ã§ã¯ãªãã
äŸ ïŒ
(1) æåç¹å®æ§IgEãã©ã°ã¡ã³ãã®èª¿è£œ
IgEâ骚é«è
«æ£è
ããã®IgEãç¡«é
žã¢ã³ã¢ããŠ
ã ã®40ïŒ é£œå溶液ã§æ²ã§ãããããããŠ0.05ã
0.5Mç·åœ¢åŸæã®TRISâHClç·©è¡æ¶²ãPH8.0ã䜿ã€
ãŠDEAE Sephadex â50ã«ã©ã ïŒPharmaciaïŒ
äžã§åé¢ããã次ãã§ãã®IgEãPBSäžã®
Ultrogel ACA ïŒâïŒïŒLKBïŒã®2.5Ã100cmã«ã©
ã äžã®ã¯ãããã°ã©ãã€ã«ãã€ãŠããã«ç²Ÿè£œã
ããæçµçæç©ïŒ10ã15ïœïŒIgEïŒã®å¯èœãªæ±
æã«ã€ããŠã¯IgGãIgAããã³IgMãå ç«æ¯æ¿èš
ã«ãã€ãŠããšãã¯ãããIgGã ããæ€åºãããã
ãŠããã¯å šã¿ã³ãã¯è³ªã®0.5ïŒ ããå°ãæ¿åºŠã§ã
ã€ãã
ã ã®40ïŒ é£œå溶液ã§æ²ã§ãããããããŠ0.05ã
0.5Mç·åœ¢åŸæã®TRISâHClç·©è¡æ¶²ãPH8.0ã䜿ã€
ãŠDEAE Sephadex â50ã«ã©ã ïŒPharmaciaïŒ
äžã§åé¢ããã次ãã§ãã®IgEãPBSäžã®
Ultrogel ACA ïŒâïŒïŒLKBïŒã®2.5Ã100cmã«ã©
ã äžã®ã¯ãããã°ã©ãã€ã«ãã€ãŠããã«ç²Ÿè£œã
ããæçµçæç©ïŒ10ã15ïœïŒIgEïŒã®å¯èœãªæ±
æã«ã€ããŠã¯IgGãIgAããã³IgMãå ç«æ¯æ¿èš
ã«ãã€ãŠããšãã¯ãããIgGã ããæ€åºãããã
ãŠããã¯å šã¿ã³ãã¯è³ªã®0.5ïŒ ããå°ãæ¿åºŠã§ã
ã€ãã
IgEã¯0.1Mé
¢é
žå¡©ç·©è¡æ¶²ãPH4.5ã®äžã§24æé
37âã§é µçŽ æ§ã¿ã³ãã¯æ¯çïŒïŒ50ïŒééïŒééïŒ
ããã€çµæ¶æ§ããã·ã³ã§æ¶åãããåºäœTRISã§
PHã8.0ã«äžããããšã«ãã€ãŠãã®åå¿ã¯æ¢ãã
ããããããŠãã®æ··åç©ãRBSäžã®Ultrogel
ACA4âïŒã®2.5Ã100cmã«ã©ã äžã§ãéãããã
ã®ã«ã©ã ã«ãã€ãŠæ¶åãããæ··åç©ã¯ååãµã€ãº
ïŒ30000ããã€ïŒã€ã®ããŒã¯ãšå°ããããããã®
ïŒã€ã®ããŒã¯ã«åé¢ãããã第ïŒäž»ããŒã¯äžã®
Fcâ³ãã©ã°ã¡ã³ããIgEã®æåç¹å®æ§ãã©ã°ã¡ã³
ããšããŠéžã°ãããããã¯IgEé µçŽ æ§æ¶åã®æ¢ç¥
ã®ãã©ã°ã¡ã³ãã§ãããããã¯IgEã®ïŒŠïŒabâ²ïŒ2ãš
Fcéšåã®äž¡æ¹ã«é¢ä¿ããæåæ§æ±ºå®å åãå«æ
ããã
37âã§é µçŽ æ§ã¿ã³ãã¯æ¯çïŒïŒ50ïŒééïŒééïŒ
ããã€çµæ¶æ§ããã·ã³ã§æ¶åãããåºäœTRISã§
PHã8.0ã«äžããããšã«ãã€ãŠãã®åå¿ã¯æ¢ãã
ããããããŠãã®æ··åç©ãRBSäžã®Ultrogel
ACA4âïŒã®2.5Ã100cmã«ã©ã äžã§ãéãããã
ã®ã«ã©ã ã«ãã€ãŠæ¶åãããæ··åç©ã¯ååãµã€ãº
ïŒ30000ããã€ïŒã€ã®ããŒã¯ãšå°ããããããã®
ïŒã€ã®ããŒã¯ã«åé¢ãããã第ïŒäž»ããŒã¯äžã®
Fcâ³ãã©ã°ã¡ã³ããIgEã®æåç¹å®æ§ãã©ã°ã¡ã³
ããšããŠéžã°ãããããã¯IgEé µçŽ æ§æ¶åã®æ¢ç¥
ã®ãã©ã°ã¡ã³ãã§ãããããã¯IgEã®ïŒŠïŒabâ²ïŒ2ãš
Fcéšåã®äž¡æ¹ã«é¢ä¿ããæåæ§æ±ºå®å åãå«æ
ããã
IgE50mgããFcâ³ãã©ã°ã¡ã³ãçŽ1.5mgãååã
ãããããã¯280nmïŒE280 1%1cmïŒ18.06ïŒã§ã®åžå
ã«ãã€ãŠè©äŸ¡ããããã®ã§ãã€ããåçµç¶æ ã§ã®
貯èµäžã«ãããåéãé¿ããããã«ããã®ç©è³ªã¯
ã¢ãžåãããªãŠã ïŒïœïŒãå«ãå¡©æ°Žäžã«ïŒâã«
ä¿ãããã
ãããããã¯280nmïŒE280 1%1cmïŒ18.06ïŒã§ã®åžå
ã«ãã€ãŠè©äŸ¡ããããã®ã§ãã€ããåçµç¶æ ã§ã®
貯èµäžã«ãããåéãé¿ããããã«ããã®ç©è³ªã¯
ã¢ãžåãããªãŠã ïŒïœïŒãå«ãå¡©æ°Žäžã«ïŒâã«
ä¿ãããã
1.5mgïŒmlã®æ¿åºŠã«ãããFcâ³ãã©ã°ã¡ã³ãã®å
åéã¯32000ãã«ãã³ãšè©äŸ¡ãããã
åéã¯32000ãã«ãã³ãšè©äŸ¡ãããã
(2) Fcâ³ãã©ã°ã¡ã³ãã«å¯Ÿããæè¡æž
ã®èª¿è£œ
çççé£å¡©æ°Ž500ÎŒããã³å®å
šããã€ã³ãã¢
ãžãŠãã³ã500ÎŒäžã®Fcâ³ãã©ã°ã¡ã³ã100ÎŒïœã
ïŒé±éæ¯ã«å€ãã®äœçœ®ã«ç®äžæ³šå°ããããšã«ãã€
ãŠãïŒå¹ã®ããŠãŒãžãŒã©ã³ãã©ãããã«ãããŠ
IgEã®Fcâ³ãã©ã°ã¡ã³ãã«å¯Ÿããæè¡æž ãç£çã
ããããã®åç©ã¯ç¬¬ïŒåã®æ³šå°åŸã«è¡ãæ¡ãã
ããFcâ³ãã©ã°ã¡ã³ãã«å¯Ÿãç¹ç°çã§ãªãæäœã
é€ãããã«IgG Sepharoseå ç«åžçã«ã©ã ãéé
ãããããšã«ãã€ãŠæè¡æž ãç¹ç°çãªãã®ãšã
ãã
ãžãŠãã³ã500ÎŒäžã®Fcâ³ãã©ã°ã¡ã³ã100ÎŒïœã
ïŒé±éæ¯ã«å€ãã®äœçœ®ã«ç®äžæ³šå°ããããšã«ãã€
ãŠãïŒå¹ã®ããŠãŒãžãŒã©ã³ãã©ãããã«ãããŠ
IgEã®Fcâ³ãã©ã°ã¡ã³ãã«å¯Ÿããæè¡æž ãç£çã
ããããã®åç©ã¯ç¬¬ïŒåã®æ³šå°åŸã«è¡ãæ¡ãã
ããFcâ³ãã©ã°ã¡ã³ãã«å¯Ÿãç¹ç°çã§ãªãæäœã
é€ãããã«IgG Sepharoseå ç«åžçã«ã©ã ãéé
ãããããšã«ãã€ãŠæè¡æž ãç¹ç°çãªãã®ãšã
ãã
åŸãããæè¡æž
ã®ç¹ç°æ§ããã¹ãããããã«å
ã®IgEã®ïŒŠïŒabâ²ïŒ2ããã³Fcã®äž¡æ¹ã§äºéå ç«æ¡æ£
ãã¹ããè¡ã€ãããã®çµæã¯æè¡æž ã¯å°ãFcâ³ã
ã©ã°ã¡ã³ãã«åããããŠããããšã瀺ããããã®
ããã«ããŠãã®æè¡æž ã¯å šäœã®IgEãããªãã¡Fc
ãŸãã¯ïŒŠïŒabâ²ïŒ2ãã©ã°ã¡ã³ãããŸãã¯Îµâéã«å¯Ÿ
ããŠåããããæè¡æž ãããããããŠããïŒæ¬çº
æã®åæç®çã«å¯ŸããŠïŒããããã¯ãã®ç¹ç°æ§ã
ç±ããã³çšããã¿ã³ãã¯é µçŽ ã«æµæã®ãã決å®èŠ
å ã«å¶éãããããã§ããã
ã®IgEã®ïŒŠïŒabâ²ïŒ2ããã³Fcã®äž¡æ¹ã§äºéå ç«æ¡æ£
ãã¹ããè¡ã€ãããã®çµæã¯æè¡æž ã¯å°ãFcâ³ã
ã©ã°ã¡ã³ãã«åããããŠããããšã瀺ããããã®
ããã«ããŠãã®æè¡æž ã¯å šäœã®IgEãããªãã¡Fc
ãŸãã¯ïŒŠïŒabâ²ïŒ2ãã©ã°ã¡ã³ãããŸãã¯Îµâéã«å¯Ÿ
ããŠåããããæè¡æž ãããããããŠããïŒæ¬çº
æã®åæç®çã«å¯ŸããŠïŒããããã¯ãã®ç¹ç°æ§ã
ç±ããã³çšããã¿ã³ãã¯é µçŽ ã«æµæã®ãã決å®èŠ
å ã«å¶éãããããã§ããã
ãã®ããã«ããŠäœãããæè¡æž
ã¯IgEã®åæ
ïŒãã®Fcâ³ãã©ã°ã¡ã³ããçµç±ããŠã®ïŒã®ããã®
æ¬çºæã®æ¹æ³ã«ãããŠäœ¿ãããšãã§ãããããã
æ¬çºæè ã¯åæã«ãããŠæäœæåãšããŠäœ¿ãã¹ã
ãã®ïŒŠïŒabâ²ïŒ2ãã©ã°ã¡ã³ã調補ã®ããã«ç²Ÿè£œãäž
èšã«è¿°ã¹ãã
ïŒãã®Fcâ³ãã©ã°ã¡ã³ããçµç±ããŠã®ïŒã®ããã®
æ¬çºæã®æ¹æ³ã«ãããŠäœ¿ãããšãã§ãããããã
æ¬çºæè ã¯åæã«ãããŠæäœæåãšããŠäœ¿ãã¹ã
ãã®ïŒŠïŒabâ²ïŒ2ãã©ã°ã¡ã³ã調補ã®ããã«ç²Ÿè£œãäž
èšã«è¿°ã¹ãã
(3) æè¡æž
ã®ïŒŠïŒabâ²ïŒ2ãã©ã°ã¡ã³ãã®èª¿è£œ
äžèš(2)ã§äœã€ãæè¡æž
ãIgGæäœãæ²ãã§ãã
ããã«ç¡«é žã¢ã³ã¢ããŠã ã§åŠçããããã次ã«
DEAEã»ã«ããŒã¹äžã§ã¯ãããã°ã©ãã«ãããã
ããã0.1Mé ¢é žå¡©ç·©è¡æ¶²PH4.5äžã§24æé37âã§
ããã·ã³æ¶åã«ããããããã®ãšãé µçŽ ïŒã¿ã³ã
ã¯è³ªã®æ¯çïŒïŒ50ïŒééïŒééïŒãçšãããPHã
7.2ã«äžããããã«åºäœã®TRISãæ·»å ããããšã«
ãã€ãŠåå¿ãæ¢ãããããŠçæãããïŒabâ²ïŒ2ã
1Må¡©åãããªãŠã ç·©è¡æ¶²ãš1/5ïŒããé žå¡©ç·©è¡æ¶²
äžPH7.2ã§Ultrogen ACA ïŒâïŒã«ã©ã äžã§ãé
ã«ãã€ãŠååãããæ¿çž®ããããŠçççé£å¡©æ°Žäž
ãžéæããåŸïŒŠïŒabâ²ïŒ2ãã©ã°ã¡ã³ãã®ïŒãïŒmgïŒ
mlã®éšåæšæ¬ãã¢ãžåãããªãŠã ïŒïœïŒã®ååš
äžã«ïŒâã§è²¯èµãããã
ããã«ç¡«é žã¢ã³ã¢ããŠã ã§åŠçããããã次ã«
DEAEã»ã«ããŒã¹äžã§ã¯ãããã°ã©ãã«ãããã
ããã0.1Mé ¢é žå¡©ç·©è¡æ¶²PH4.5äžã§24æé37âã§
ããã·ã³æ¶åã«ããããããã®ãšãé µçŽ ïŒã¿ã³ã
ã¯è³ªã®æ¯çïŒïŒ50ïŒééïŒééïŒãçšãããPHã
7.2ã«äžããããã«åºäœã®TRISãæ·»å ããããšã«
ãã€ãŠåå¿ãæ¢ãããããŠçæãããïŒabâ²ïŒ2ã
1Må¡©åãããªãŠã ç·©è¡æ¶²ãš1/5ïŒããé žå¡©ç·©è¡æ¶²
äžPH7.2ã§Ultrogen ACA ïŒâïŒã«ã©ã äžã§ãé
ã«ãã€ãŠååãããæ¿çž®ããããŠçççé£å¡©æ°Žäž
ãžéæããåŸïŒŠïŒabâ²ïŒ2ãã©ã°ã¡ã³ãã®ïŒãïŒmgïŒ
mlã®éšåæšæ¬ãã¢ãžåãããªãŠã ïŒïœïŒã®ååš
äžã«ïŒâã§è²¯èµãããã
(4) ïŒabâ²ïŒ2ãã©ã°ã¡ã³ãã§ã³ãŒãã³ã°ããã©ã
ãã¯ã¹ 10ïŒ ïŒééïŒäœç©ïŒã©ããã¯ã¹ïŒ0.8ÎŒïŒæžæ¿æ¶²
100ÎŒã«ãïŒabâ²ïŒ2ãã©ã°ã¡ã³ã300ÎŒïŒå šéé
ïŒ1.2mgïŒããã³ïŒåã«åžéã®ã°ãªã·ã³ç·©è¡é£å¡©
æ°ŽïŒ0.17Mã°ãªã·ã³ã0.1M NaCläžã«å«ã¿
NaOHã§PH9.2ã«èª¿ç¯ããããŠã¢ãžåãããªãŠã
ä¿åå€0.4ïœïŒãå«æïŒ800ÎŒã®æ··åç©ãå ã
ãã30åé宀枩ã«ä¿æž©ããåŸã©ããã¯ã¹ãïŒåºŠïŒ
ååžéã®ã°ã·ã·ã³ç·©è¡é£å¡©æ°ŽïŒmlã§ããããŠçã®
è¡æž ã¢ã«ããã³ïŒGBSâBSAïŒ10ïœïŒãå«ã
ç·©è¡é£å¡©æ°ŽïŒmlã§ïŒåºŠæŽã€ããGBSâBSA2mläž
ã«åæžæ¿ããããŠ10ç§éè¶ é³æ³¢åŠçåŸã©ããã¯ã¹
ãåçµä¹Ÿç¥ããããŠïŒâã§ããæ ãããã³ãã®äž
ã«è²¯ãããæ¯æ¥ã®äœ¿çšåã«ã©ããã¯ã¹ãèžçæ°Ž
200ÎŒäžã«åæžæ¿ããGBSâBSA1.8mlã§åžéã
ãããŠ10ç§éè¶ é³æ³¢åŠçããã
ãã¯ã¹ 10ïŒ ïŒééïŒäœç©ïŒã©ããã¯ã¹ïŒ0.8ÎŒïŒæžæ¿æ¶²
100ÎŒã«ãïŒabâ²ïŒ2ãã©ã°ã¡ã³ã300ÎŒïŒå šéé
ïŒ1.2mgïŒããã³ïŒåã«åžéã®ã°ãªã·ã³ç·©è¡é£å¡©
æ°ŽïŒ0.17Mã°ãªã·ã³ã0.1M NaCläžã«å«ã¿
NaOHã§PH9.2ã«èª¿ç¯ããããŠã¢ãžåãããªãŠã
ä¿åå€0.4ïœïŒãå«æïŒ800ÎŒã®æ··åç©ãå ã
ãã30åé宀枩ã«ä¿æž©ããåŸã©ããã¯ã¹ãïŒåºŠïŒ
ååžéã®ã°ã·ã·ã³ç·©è¡é£å¡©æ°ŽïŒmlã§ããããŠçã®
è¡æž ã¢ã«ããã³ïŒGBSâBSAïŒ10ïœïŒãå«ã
ç·©è¡é£å¡©æ°ŽïŒmlã§ïŒåºŠæŽã€ããGBSâBSA2mläž
ã«åæžæ¿ããããŠ10ç§éè¶ é³æ³¢åŠçåŸã©ããã¯ã¹
ãåçµä¹Ÿç¥ããããŠïŒâã§ããæ ãããã³ãã®äž
ã«è²¯ãããæ¯æ¥ã®äœ¿çšåã«ã©ããã¯ã¹ãèžçæ°Ž
200ÎŒäžã«åæžæ¿ããGBSâBSA1.8mlã§åžéã
ãããŠ10ç§éè¶ é³æ³¢åŠçããã
å
šéšã®IgGã䜿ããšãããã®ïŒŠïŒabâ²ïŒ2ãã©ã°ã¡
ã³ãããããããããããã¯äžè¬ã«åæ§ãªå·¥åã«
ã©ããã¯ã¹ç²åäžã«ã³ãŒãã€ã³ã°ãããããšãã§
ããã
ã³ãããããããããããã¯äžè¬ã«åæ§ãªå·¥åã«
ã©ããã¯ã¹ç²åäžã«ã³ãŒãã€ã³ã°ãããããšãã§
ããã
(5) æ€å®æé
PACIAã«ããåææé ã¯æ¬è³ªçã«ã¯æ¬¡ã®éã
ã§ãããïŒäžèšã®ããã«äœãããããªãã¡æè¡æž
ãŸãã¯ãã®ïŒŠïŒabâ²ïŒ2ãã©ã°ã¡ã³ãã§ã³ãŒãã³ã°ã
ããïŒã©ããã¯ã¹ã¯åæãããã¹ãè©Šæãšæ··åã
ãããã©ããã¯ã¹ã®ãããã®ã¯åéããŠãããæ®
ãã®ãã®ã¯ããã§ã¯ãªããããã§åéããªãã©ã
ãã¯ã¹ãç®ãããšãããã¯åéããã©ããã¯ã¹ã®
éã®èšéãäžããããã¯åæããŠããè©Šæäžã®
IgEãã©ã°ã¡ã³ãã®éã®é 次ã«ç€ºããã®ã§ããã
ã§ãããïŒäžèšã®ããã«äœãããããªãã¡æè¡æž
ãŸãã¯ãã®ïŒŠïŒabâ²ïŒ2ãã©ã°ã¡ã³ãã§ã³ãŒãã³ã°ã
ããïŒã©ããã¯ã¹ã¯åæãããã¹ãè©Šæãšæ··åã
ãããã©ããã¯ã¹ã®ãããã®ã¯åéããŠãããæ®
ãã®ãã®ã¯ããã§ã¯ãªããããã§åéããªãã©ã
ãã¯ã¹ãç®ãããšãããã¯åéããã©ããã¯ã¹ã®
éã®èšéãäžããããã¯åæããŠããè©Šæäžã®
IgEãã©ã°ã¡ã³ãã®éã®é 次ã«ç€ºããã®ã§ããã
人éã®è¡æž
ã«ãããŠã¯æ£åžžãªIgEãšãããŠã¢ã¬
ã«ã®ãŒæ§ã®å¿çã«è²¬ä»»ã®ããâæäœIgEâãšãã
ããã®ã§ãããIgEã®å šäœã¯å šè¡æž ãFcâ³ãã©ã°
ã¡ã³ããçããïŒãããŠä»ã®è¡æž ã¿ã³ãã¯è³ªãç Ž
å£ããïŒããã«ããã·ã³åæã«ãããããšã«ãã€
ãŠåæããããšãã§ããããã«çããFcâ³ãã©ã°
ã¡ã³ãã¯æ¬¡ã«ã©ããã¯ã¹ã䜿ã€ãŠåæããããã
ã®ä»£ããšããŠããããã®éžæãããIgEãå ãã
ããè¡æž ããéžæçã«æœåºããããã次ã«ããã
é µçŽ çã«æ¶åããŠFcâ³ãã©ã°ã¡ã³ããäžãããã
ã«ããããšã«ãã€ãŠåæããããšãã§ããããã®
éžæçæœåºã¯äŸ¿å®çäžè¿°ã®ããã«RASTã«å¯Ÿã
ããã®ã§ããããšãã§ããããªãã¡ããã¯ãã®ã¢
ã¬ã«ã®ãŒæåã«æåãããç¹æ®ãªâæäœâIgEâ
ãšéžæçã«çµåããã¢ã¬ã«ã®ãŒæåãã³ãŒãã³ã°
ããããã€ã¹ã¯ã®äœ¿çšãå«ãããšãã§ãããæŽã
ãããã€ã¹ã¯ã¯æ¬¡ã«IgEãæ¶åããããã«ãããŠ
ãããFcâ³ãã©ã°ã¡ã³ãã«å€ããããã«ããã·ã³
ãšãã€ããã«ä¿æž©ãããã
ã«ã®ãŒæ§ã®å¿çã«è²¬ä»»ã®ããâæäœIgEâãšãã
ããã®ã§ãããIgEã®å šäœã¯å šè¡æž ãFcâ³ãã©ã°
ã¡ã³ããçããïŒãããŠä»ã®è¡æž ã¿ã³ãã¯è³ªãç Ž
å£ããïŒããã«ããã·ã³åæã«ãããããšã«ãã€
ãŠåæããããšãã§ããããã«çããFcâ³ãã©ã°
ã¡ã³ãã¯æ¬¡ã«ã©ããã¯ã¹ã䜿ã€ãŠåæããããã
ã®ä»£ããšããŠããããã®éžæãããIgEãå ãã
ããè¡æž ããéžæçã«æœåºããããã次ã«ããã
é µçŽ çã«æ¶åããŠFcâ³ãã©ã°ã¡ã³ããäžãããã
ã«ããããšã«ãã€ãŠåæããããšãã§ããããã®
éžæçæœåºã¯äŸ¿å®çäžè¿°ã®ããã«RASTã«å¯Ÿã
ããã®ã§ããããšãã§ããããªãã¡ããã¯ãã®ã¢
ã¬ã«ã®ãŒæåã«æåãããç¹æ®ãªâæäœâIgEâ
ãšéžæçã«çµåããã¢ã¬ã«ã®ãŒæåãã³ãŒãã³ã°
ããããã€ã¹ã¯ã®äœ¿çšãå«ãããšãã§ãããæŽã
ãããã€ã¹ã¯ã¯æ¬¡ã«IgEãæ¶åããããã«ãããŠ
ãããFcâ³ãã©ã°ã¡ã³ãã«å€ããããã«ããã·ã³
ãšãã€ããã«ä¿æž©ãããã
è¡æž
äžã®å
šéšã®IgEã®åæã«ãããŠã¯ããã®è¡
æž ã¯å ãç容ç©ã®ãã¬ãªã³113ïŒãã¬ãªã³ã¯ç»é²å
æšã§ããïŒã§æž æµåããã枊åããã³åå¿åé¢ã
ïŒåé5000å転ïŒåã§è¡ããæž æµãªäžæŸæ¶²ã®çŽ
100ÎŒã®éšåæšæ¬ã次ã«10åé37âã§HClâãã
ã·ã³ïŒ0.15ã¢ã«ïŒHClïŒïŒïœïŒïŒåã®åçµæ¶
ããããã·ã³ïŒãšãã€ããã«ä¿æž©ãããïŒã¢ã«ïŒ
TRIS 20ÎŒãæ·»å ããŠæ¶åãæ¢ããããã
ããŠã§ããæ··åç©ã次ã«ã©ããã¯ã¹ç²åã䜿ã€ãŠ
åæããã
æž ã¯å ãç容ç©ã®ãã¬ãªã³113ïŒãã¬ãªã³ã¯ç»é²å
æšã§ããïŒã§æž æµåããã枊åããã³åå¿åé¢ã
ïŒåé5000å転ïŒåã§è¡ããæž æµãªäžæŸæ¶²ã®çŽ
100ÎŒã®éšåæšæ¬ã次ã«10åé37âã§HClâãã
ã·ã³ïŒ0.15ã¢ã«ïŒHClïŒïŒïœïŒïŒåã®åçµæ¶
ããããã·ã³ïŒãšãã€ããã«ä¿æž©ãããïŒã¢ã«ïŒ
TRIS 20ÎŒãæ·»å ããŠæ¶åãæ¢ããããã
ããŠã§ããæ··åç©ã次ã«ã©ããã¯ã¹ç²åã䜿ã€ãŠ
åæããã
äŸ ïŒ
è©Šæã®ããã·ã³åŠçã䜿ã€ãŠã®TSHåæ
åçïŒ
ã«ã«ããã·ã«åãããã©ããã¯ã¹ç²åã¯TSH
ãå«ã人éã®ç²æ¶²ã®æœåºç©ã®ã¿ã³ãã¯è³ªã¯å ±æçµ
åã§ã³ãŒãã³ã°ãããŠãããåéã¯åéå€ãšããŠ
ã©ãããã®æâTSHæäœãšäººéã®ãªãŠããå å
ïŒRFïŒã®æ··åç©ã«ãã€ãŠèµ·ããåéã¯å®éããã
ã¹ãTSHã«ãã€ãŠé»å®³ããããè©Šæã®ããã·ã³
åŠçã¯è¡æž ã®å¹²æžãç Žå£ãããé µçŽ æ¶åæ¡ä»¶ã¯
TSHãå ç«åŠçã«åå¿æ§ã«æ®ããã®ãããªæ¡ä»¶
ã§ãããããªãã¡ããã¯å®è³ªçã«æ¶åã«ãã€ãŠåœ±
é¿ãåããªãã
ãå«ã人éã®ç²æ¶²ã®æœåºç©ã®ã¿ã³ãã¯è³ªã¯å ±æçµ
åã§ã³ãŒãã³ã°ãããŠãããåéã¯åéå€ãšããŠ
ã©ãããã®æâTSHæäœãšäººéã®ãªãŠããå å
ïŒRFïŒã®æ··åç©ã«ãã€ãŠèµ·ããåéã¯å®éããã
ã¹ãTSHã«ãã€ãŠé»å®³ããããè©Šæã®ããã·ã³
åŠçã¯è¡æž ã®å¹²æžãç Žå£ãããé µçŽ æ¶åæ¡ä»¶ã¯
TSHãå ç«åŠçã«åå¿æ§ã«æ®ããã®ãããªæ¡ä»¶
ã§ãããããªãã¡ããã¯å®è³ªçã«æ¶åã«ãã€ãŠåœ±
é¿ãåããªãã
æ€å®ïŒ
è©ŠæåŠçïŒ
ãªã³é
žå¡©ã§ç·©è¡ãããããŠçã®è¡æž
ã¢ã«ããã³
ïŒBSAïŒïŒïŒ ãå«æããå¡©é¡æº¶æ¶²ã§ããè©Šæ10ÎŒ
ãããã·ã³ïŒmlïŒãå«æãã0.15Nã®HCl
100ÎŒãšæ··åãããä¿æž©æéã¯å®€æž©ã§10åéãš
ãããããã·ã³ã«ããæ¶åãäžæ¢ããããã«18ïŒ
ããªãšãã¬ã³ã°ãªã³ãŒã«ïŒPEGïŒ6000ãå«æã
ã0.3ïŒ Na2HPO4100ÎŒãæ·»å ããã
ïŒBSAïŒïŒïŒ ãå«æããå¡©é¡æº¶æ¶²ã§ããè©Šæ10ÎŒ
ãããã·ã³ïŒmlïŒãå«æãã0.15Nã®HCl
100ÎŒãšæ··åãããä¿æž©æéã¯å®€æž©ã§10åéãš
ãããããã·ã³ã«ããæ¶åãäžæ¢ããããã«18ïŒ
ããªãšãã¬ã³ã°ãªã³ãŒã«ïŒPEGïŒ6000ãå«æã
ã0.3ïŒ Na2HPO4100ÎŒãæ·»å ããã
ãã®ããã«åŠçãããè©Šæ30ÎŒãåŒç¶ããŠã©
ãããã®æâTSHïŒPBSâ0.1ïŒ BSAäžã«åžéã
ããã®ïŒ30ÎŒã人éã®RFïŒPBSâ0.1ïŒ BSAäž
ã«åžéãããã®ïŒ30ÎŒããã³ã©ããã¯ã¹ç²å
ïŒPBSâ0.1ïŒ BSAäžã«æžæ¿ãããã®ïŒ30ÎŒãšæ··
åããã
ãããã®æâTSHïŒPBSâ0.1ïŒ BSAäžã«åžéã
ããã®ïŒ30ÎŒã人éã®RFïŒPBSâ0.1ïŒ BSAäž
ã«åžéãããã®ïŒ30ÎŒããã³ã©ããã¯ã¹ç²å
ïŒPBSâ0.1ïŒ BSAäžã«æžæ¿ãããã®ïŒ30ÎŒãšæ··
åããã
ä¿æž©æéã¯37âã§25åãšããããã®æ€å®ç³»ã®æ
床ã¯0.1nïœ TSHïŒmlã§ããã
床ã¯0.1nïœ TSHïŒmlã§ããã
æ·»ä»å³é¢ã¯ããã·ã³æº¶é¢æ³ã«ãã€ãŠåŸãããçµ
æã«ã€ããŠãã©ããã¯ã¹æ³ãšRASTæ³ãšã®çžé¢
ã瀺ãçžé¢å³ã§ããã ã€ã¯RASTæ³ã«ãããã€ãã¹ããã¯RASTæ³
ã«ãããã©ã¹å€ããã¯ã©ããã¯ã¹æ³ã«ããã€ã
ã¹ããããŠãã¯ã©ããã¯ã¹æ³ã«ãããã©ã¹å€ãå
瀺ãã
æã«ã€ããŠãã©ããã¯ã¹æ³ãšRASTæ³ãšã®çžé¢
ã瀺ãçžé¢å³ã§ããã ã€ã¯RASTæ³ã«ãããã€ãã¹ããã¯RASTæ³
ã«ãããã©ã¹å€ããã¯ã©ããã¯ã¹æ³ã«ããã€ã
ã¹ããããŠãã¯ã©ããã¯ã¹æ³ã«ãããã©ã¹å€ãå
瀺ãã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ æ€å®å¯Ÿè±¡ã®ã¿ã³ãã¯è³ªããã³ãã®ä»ã®ïŒçš®ãŸ
ãã¯ãã以äžã®æ€å®å¯Ÿè±¡å€ã®ã¿ã³ãã¯è³ªãå«ã液
äœè©Šæãšã¿ã³ãã¯è³ªæ¶åå€ãšãæ··åããæååŠç
ã«åèšã®å¯Ÿè±¡ã¿ã³ãã¯è³ªã®ã¿ã«ç¹ç°çã«ååšãã
ãã©ã°ã¡ã³ããåèšã®å¯Ÿè±¡ã¿ã³ãã¯è³ªãæ¶åã«ã
ãåèšæ··åç©äžã«ç£çããæ¡ä»¶äžã§ãã¿ã³ãã¯è³ª
æ¶åãè¡ãããšã«ãã€ãŠãåèšã®å¯Ÿè±¡å€ã¿ã³ãã¯
質ã«ããå¹²æžã軜æžãªããæé€ãããããŠåèšã®
ç¹ç°çãã©ã°ã¡ã³ãã«å¯Ÿããæäœãšã®åå¿ã«ãã
該ãã©ã°ã¡ã³ããæ€å®ãããããŠãã®çµæãã液
äœè©Šæäžã«ååšããåèšã®å¯Ÿè±¡ã¿ã³ãã¯è³ªã®éã
決å®ããããšããæãã察象å€ã¿ã³ãã¯è³ªïŒçš®ãŸ
ãã¯ãã以äžãå«ã液äœè©Šæäžã®å¯Ÿè±¡ã¿ã³ãã¯è³ª
ã®å ç«åŠçæ€å®æ³ã ïŒ åèšæ¶åå€ãšããŠé µçŽ ã䜿ããåèšã®å¯Ÿè±¡ã¿
ã³ãã¯è³ªããã®é µçŽ ã§å解ããŠç¹ç°çãã©ã°ã¡ã³
ããç£çãããåé ïŒã«èšèŒã®æ¹æ³ã ïŒ ç¹ç°çãã©ã°ã¡ã³ãã«å¯Ÿããæäœã®ïŒŠïŒabïŒ
é åãšåå¿ãããããšã«ãã€ãŠç¹ç°çãã©ã°ã¡ã³
ããæ€å®ãããåé ïŒã«èšèŒã®æ¹æ³ã ïŒ æäœå šäœãšåå¿ãããããšã«ãã€ãŠç¹ç°çã
ã©ã°ã¡ã³ããæ€å®ãããåé ïŒã«èšèŒã®æ¹æ³ã ïŒ æäœã®ïŒŠïŒabâ²ïŒ2ãã©ã°ã¡ã³ããšåå¿ãããã
ãšã«ãã€ãŠç¹ç°çãã©ã°ã¡ã³ããæ€å®ãããåé
ïŒã«èšèŒã®æ¹æ³ã ïŒ åŸ®çŽ°ã«åæ£ããç²åã®åéçšåºŠãã察象ã¿ã³
ãã¯è³ªã®éã枬å®ããç²ååéæ³ã«ãã€ãŠç¹ç°ç
ãã©ã°ã¡ã³ããæ€å®ãããåé ïŒã«èšèŒã®æ¹æ³ã ïŒ æ¶²äœè©ŠæãšããŠçç©åŠçæµäœã䜿ããåé ïŒ
ã«èšèŒã®æ¹æ³ã ïŒ ã¿ã³ãã¯è³ªæ¶åå€ãšããŠããã·ã³ãããã€ã³
ããã³ããªãã·ã³ããéžãã é µçŽ ã䜿ããåé ïŒ
ã«èšèŒã®æ¹æ³ã ïŒ (a) æ€å®å¯Ÿè±¡ã®ã¿ã³ãã¯è³ªããã³ãã®ä»ã®ïŒ
çš®ãŸãã¯ãã以äžã®æ€å®å¯Ÿè±¡å€ã¿ã³ãã¯è³ªãå«
ãçç©åŠçæµäœè©Šæãšåèšè©Šæäžã®åèšå¯Ÿè±¡ã¿
ã³ãã¯è³ªã«ã ãéžæçã«çµåããåå¿äœãæ æ
ããäžæŽ»æ§åºäœæ¯æäœææãšãæ¥è§Šããã (b) è©Šæããã察象ã¿ã³ãã¯è³ªãæ æããåèšæ¯
æäœææãåãåºãã (c) åèšã®åãåºãã察象ã¿ã³ãã¯è³ªããæååŠ
çã«å¯Ÿè±¡ã¿ã³ãã¯è³ªã®ã¿ã«ç¹ç°çã«ååšããã
ã©ã°ã¡ã³ãã圢æããæ¡ä»¶äžã§åèšã®åãåºã
ã察象ã¿ã³ãã¯è³ªãæ¶åãããã㊠(d) åèšã®ç¹ç°çãã©ã°ã¡ã³ãã«å¯Ÿããæäœãšã®
åå¿ã«ãã該ãã©ã°ã¡ã³ããæ€å®ãããã®çµæ
ãã液äœè©Šæäžã®å¯Ÿè±¡ã¿ã³ãã¯è³ªã®éã決å®ã
ã ããšããæãã察象å€ã¿ã³ãã¯è³ªã«ããæ€å®å¹²æž
ãæé€ããæ€å®ã®ç¹ç°æ§ãšæ£ç¢ºæ§ãšãæ¹è¯ããã
察象å€ã¿ã³ãã¯è³ªïŒçš®ãŸãã¯ãã以äžãå«ãçç©
åŠçæµäœè©Šæäžã®å¯Ÿè±¡ã¿ã³ãã¯è³ªã®æ€å®æ¹æ³ã ïŒïŒ åèšã®å¯Ÿè±¡ã¿ã³ãã¯è³ªãšããŠç¹å®IgEæäœ
ã䜿ããåèšã®å¯Ÿè±¡å€ã¿ã³ãã¯è³ªãåèšã®äžæŽ»æ§
åºäœæ¯æäœææäžã®åå¿äœãšçµåã§ããªãä»ã®
IgEå°ããšãïŒåãå«ãã§ãããã®ã䜿ããåé
ïŒã«èšèŒã®æ¹æ³ã ïŒïŒ äžæŽ»æ§åºäœæ¯æäœææãšããŠç¹å®IgEã«å¯Ÿ
ããã¢ã¬ã«ã²ã³ãæ æããã·ãŒãç¶ææã䜿ãã
åé ïŒïŒã«èšèŒã®æ¹æ³ã ïŒïŒ å·¥çš(d)ã«ãããŠç¹ç°çãã©ã°ã¡ã³ãããã
ãšåå¿æ§ã®ããæäœã®ïŒŠïŒabïŒé åãšã®åå¿ã«ã
ã€ãŠæ€å®ãããããŠãã®æ€å®ãç²ååéæ³ã«ãã€
ãŠè¡ããåé ïŒã«èšèŒã®æ¹æ³ã ïŒïŒ ç¹ç°çãã©ã°ã¡ã³ããæäœå šäœãšã®åå¿ã«
ãã€ãŠæ€å®ãããåé ïŒïŒã«èšèŒã®æ¹æ³ã ïŒïŒ ç¹ç°çãã©ã°ã¡ã³ããæäœã®ïŒŠïŒabâ²ïŒ2ãã©
ã°ã¡ã³ããšã®åå¿ã«ãã€ãŠæ€å®ãããåé ïŒïŒã«
èšèŒã®æ¹æ³ã ïŒïŒ å·¥çš(c)ã«ãããæ¶åãé µçŽ ã«ãã€ãŠè¡ãã
åé ïŒã«èšèŒã®æ¹æ³ã ïŒïŒ (a) æ€å®å¯Ÿè±¡ã®ã¿ã³ãã¯è³ªã®è©Šæã«ã€ããŠ
皮皮ã®æ¡ä»¶äžã§äºåçãªé µçŽ çæ¶åãè¡ããç
æããã¿ã³ãã¯è³ªåç»ãåé¢ããæååŠçã«å
èšã®å¯Ÿè±¡ã¿ã³ãã¯è³ªã®ã¿ã«ç¹ç°çã«ååšããã
ã©ã°ã¡ã³ããç£çããæ¶åæ¡ä»¶ã決å®ãã (b) åèšå·¥çš(a)ã§æ±ºå®ããæ¶åæ¡ä»¶ã䜿ã€ãŠãæ€
å®å¯Ÿè±¡ã®ã¿ã³ãã¯è³ªããã³ãã®ä»ã®ïŒçš®ãŸãã¯
ãã以äžã®æ€å®å¯Ÿè±¡å€ã¿ã³ãã¯è³ªãå«ã液äœè©Š
æãé µçŽ çã«æ¶åãã (c) æ¶åãæ¢ãããã㊠(d) åŸãããæ··åç©ãæ€å®ããŠãã®äžã«ãããæ
ååŠçã«å¯Ÿè±¡ã¿ã³ãã¯è³ªã®ã¿ã«ç¹ç°çãªãã©ã°
ã¡ã³ãã®éã決å®ãããããŠãã®çµæãã液äœ
è©Šæäžã®å¯Ÿè±¡ã¿ã³ãã¯è³ªã®éã決å®ãã ããšããæããåèšã®å¯Ÿè±¡å€ã¿ã³ãã¯è³ªããã®å¹²
æžã軜æžãªããæé€ããã察象å€ã¿ã³ãã¯è³ªïŒçš®
ãŸãã¯ãã以äžãå«ã液äœè©Šæäžã®å¯Ÿè±¡ã¿ã³ãã¯
質ã®æ€å®æ¹æ³ã ïŒïŒ 液äœè©ŠæãšããŠããã®è¡æž ã䜿ããé µçŽ ãš
ããŠããã·ã³ã䜿ããå·¥çš(d)ã«ãããç¹ç°çãã©
ã°ã¡ã³ãã®æ€å®ã埮现ã«åæ£ããç²åã®ååšäžã§
ç¹ç°çãã©ã°ã¡ã³ãã«å¯ŸããæäœïŒŠïŒabïŒé åãš
ã®åå¿ã«ãã€ãŠè¡ããåèšç²åã®åéã®çšåºŠã枬
å®ããããšã«ãã€ãŠç¹ç°çãã©ã°ã¡ã³ãéã決å®
ãããåé ïŒïŒã«èšèŒã®æ¹æ³ã ïŒïŒ ç¹ç°çãã©ã°ã¡ã³ãã«å¯Ÿããæäœå šäœãšã®
åå¿ã«ãã€ãŠæ€å®ãè¡ããåé ïŒïŒã«èšèŒã®æ¹
æ³ã ïŒïŒ ç¹ç°çãã©ã°ã¡ã³ãã«å¯Ÿããæäœã®ïŒŠ
ïŒabâ²ïŒ2ãã©ã°ã¡ã³ããšã®åå¿ã«ãã€ãŠæ€å®ãè¡
ããåé ïŒïŒã«èšèŒã®æ¹æ³ã
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8035794 | 1980-11-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57108666A JPS57108666A (en) | 1982-07-06 |
| JPH0221548B2 true JPH0221548B2 (ja) | 1990-05-15 |
Family
ID=10517154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56177847A Granted JPS57108666A (en) | 1980-11-07 | 1981-11-07 | Immunologic inspection of protein |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4455381A (ja) |
| EP (1) | EP0051985B2 (ja) |
| JP (1) | JPS57108666A (ja) |
| AU (1) | AU548783B2 (ja) |
| CA (1) | CA1180274A (ja) |
| DE (1) | DE3168691D1 (ja) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3266967D1 (en) * | 1982-01-05 | 1985-11-21 | Int Inst Cellular Molecul Path | Method of immunoassay |
| DE3366740D1 (en) * | 1982-08-06 | 1986-11-13 | Int Inst Cellular Molecul Path | Particle agglutination assay of antigens |
| US4539292A (en) * | 1982-12-29 | 1985-09-03 | Reid Michael J | Immunoassay technique for specific immunoglobulin E |
| US4650751A (en) * | 1983-04-29 | 1987-03-17 | Technicon Instruments Corporation | Protected binding assay avoiding non-specific protein interference |
| FR2549230B1 (fr) * | 1983-06-14 | 1986-04-11 | Bio Merieux | Procede de detection d'un oligomere dans un milieu liquide contenant des monomeres correspondants, dispositif pour la mise en oeuvre de ce procede et application notamment a la recherche d'allergenes |
| US4668620A (en) * | 1984-02-22 | 1987-05-26 | Syntex (U.S.A.) Inc. | Reducing background interference activity in enzyme-label immunoassays |
| BE899664A (fr) * | 1984-05-15 | 1984-08-31 | Inst Internat De Pathologie Ce | Procede de dosage immunologique d'une substance dans un echantillon liquide. |
| WO1986005593A1 (en) * | 1985-03-18 | 1986-09-25 | The Royal Free Hospital School Of Medicine | Improvements relating to the detection of viruses and antibodies |
| US5242802A (en) * | 1985-03-29 | 1993-09-07 | Hybritech Incorporated | Processes for the stabilization of prostate specific antigen in natural matrices |
| GB8621495D0 (en) * | 1986-09-05 | 1986-10-15 | Acade Diagnostic Systems Sa Nv | Assay |
| JP2523171B2 (ja) * | 1987-08-12 | 1996-08-07 | åžäººæ ªåŒäŒç€Ÿ | å ç«æž¬å®æ¹æ³åã³ããã«çšããè©Šè¬ããã |
| TW517059B (en) * | 1994-07-25 | 2003-01-11 | Ciba Geigy Ag | New process for the production of biologically active protein |
| US6066464A (en) * | 1996-12-10 | 2000-05-23 | Diagnostic Systems Laboratories, Inc. | Immunoassay of IGF family of peptides, their binding proteins and related molecules in dried whole blood filter paper spots |
| ATE239230T1 (de) * | 1998-10-15 | 2003-05-15 | Halmon Lab Beheer B V | Verbessertes verfahren zur bestimmung von allergien |
| GB9827845D0 (en) * | 1998-12-17 | 1999-02-10 | Scolab S A | Immunoassay or proteins |
| WO2001092885A1 (fr) * | 2000-05-30 | 2001-12-06 | Iatron Laboratories, Inc. | Methode immunologique de turbidimetrie provoquee par du latex et reactif pour la mise en oeuvre de ladite methode |
| US7402423B2 (en) * | 2004-08-13 | 2008-07-22 | Biomed Solutions, Llc | Apparatus for the detection of pepsin |
| US20070077546A1 (en) * | 2005-08-10 | 2007-04-05 | Zhenghua Ji | Concentration techniques in chromatographic separation |
| US7422866B2 (en) * | 2005-08-10 | 2008-09-09 | Agilent Technologies, Inc. | On-line enzymatic digestion in separation-detection methods |
| US7998749B2 (en) | 2005-10-12 | 2011-08-16 | Allergan, Inc. | Assays of molecular or subcellular interactivity using depolarization after resonance transfer energy (DARET) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5417115A (en) * | 1977-04-27 | 1979-02-08 | Chandon Investment Planning | Overall quantitative measuring of hormone and drugs |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3962039A (en) * | 1974-08-08 | 1976-06-08 | Center For Laboratory Medicine | Analytical procedure for thyroid hormones |
| JPS5236091A (en) * | 1975-09-15 | 1977-03-19 | Abbott Lab | Analytical method using digestive enzyme for serum connective protein |
| ES471585A1 (es) * | 1977-07-15 | 1979-01-16 | Behringwerke Ag | Procedimiento para la determinacion de reactivos fc |
| GB2013211B (en) * | 1978-01-26 | 1982-06-30 | Technicon Instr | Immunoassays using f(ab')2 fragments |
| GB2013688B (en) * | 1978-01-26 | 1982-06-30 | Technicon Instr | Insolubilised proteins and immunoassays utilising them |
| US4211762A (en) * | 1978-01-26 | 1980-07-08 | Huggins Keith G | Specific binding assay techniques |
-
1981
- 1981-11-05 EP EP81305261A patent/EP0051985B2/en not_active Expired
- 1981-11-05 DE DE8181305261T patent/DE3168691D1/de not_active Expired
- 1981-11-06 CA CA000389619A patent/CA1180274A/en not_active Expired
- 1981-11-06 US US06/319,023 patent/US4455381A/en not_active Expired - Lifetime
- 1981-11-06 AU AU77162/81A patent/AU548783B2/en not_active Ceased
- 1981-11-07 JP JP56177847A patent/JPS57108666A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5417115A (en) * | 1977-04-27 | 1979-02-08 | Chandon Investment Planning | Overall quantitative measuring of hormone and drugs |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0051985B2 (en) | 1989-12-27 |
| AU7716281A (en) | 1982-05-13 |
| EP0051985A2 (en) | 1982-05-19 |
| CA1180274A (en) | 1985-01-02 |
| US4455381A (en) | 1984-06-19 |
| EP0051985B1 (en) | 1985-01-30 |
| DE3168691D1 (en) | 1985-03-14 |
| JPS57108666A (en) | 1982-07-06 |
| EP0051985A3 (en) | 1982-08-11 |
| AU548783B2 (en) | 1986-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0221548B2 (ja) | ||
| US4683295A (en) | Method for the preparation of anti-receptor antibodies | |
| JP2003530541A (ja) | çç©åŠçè©Šæã«ãããééåžžäŒéå åæ ªã«ãã£ãŠåŒèµ·ããããäºæ¥æ§äŒéæ§æµ·ç¶¿ç¶è³çã®èšºææ¹æ³ | |
| EP0185722A1 (en) | Polyclonal antibodies, preparation and use | |
| Wal et al. | Enzyme immunoassay of specific human IgE to purified cowsâ milk allergens | |
| EP0064274A1 (en) | Method for assaying antigen-antibody reactions and reagent therefor | |
| CN113447659B (zh) | äžç§æ£æµæèçœé ¶äœäºåºÎ±1-IgGæäœçè¯åç | |
| CN113447658B (zh) | äžç§æ£æµæè¿æ°§åç©è¿åé ¶-1-IgGæäœçè¯åç | |
| US4239743A (en) | Carrier-bound immunoglobulin fission product and its use in immunologic analyses | |
| KR910700459A (ko) | ìžì늰 ìì¡Žì± ì§ì±ë¹ëšë³ì ì¡°êž°ê²ì§ ë° ì¹ë£ë¥Œ ìí ë°©ë² ë° ì¡°ì±ë¬Œ | |
| US4454226A (en) | Enzymatic immunoassay | |
| Largman et al. | [17] Radioimmunoassay determination of circulating pancreatic endopeptidases | |
| Weltman et al. | A galactosidase immunosorbent test for human immunoglobulin E | |
| JPS637348B2 (ja) | ||
| JP3124028B2 (ja) | éå çã«ã°ãªã³ã·ã«åãããïœâæ«ç«¯ã¢ããé žã«åããããæåã䜿çšããã°ãªã³ã·ã«åãããã¿ã³ãã¯ã®å ç«åŠç枬å®æ³ | |
| Magnusson et al. | Particle counting immunoassay of immunoglobulin E antibodies after their elution from allergosorbents by pepsin: an alternative to the radioallergosorbent test | |
| EP0994353B1 (en) | Improved method for allergy diagnostics | |
| JP2002529735A (ja) | ç©é¡ã®ç©ç²ã«ãããåç©«åçºèœã®æ€åº | |
| EP0404186A2 (en) | Process of measuring specific antibody | |
| US6548260B1 (en) | Detection of PSA-α2-macroglobulin complex in a biological fluid | |
| EP1010980A1 (en) | Immunoassay of proteins | |
| EP0260079A1 (en) | Method of assay | |
| JPH0690203B2 (ja) | åç«è ºç¹ç°æåãšÎ±â²äžïŒâŒâã¢ã³ãããªãã·ã³è€åäœã®å®éæ¹æ³ | |
| CA1243944A (en) | Reagent and process for quantitatively measuring antibodies | |
| JPH0246897B2 (ja) | Amiraazeomochiitakogenketsuteikigujubutsushitsusokuteiho |